

CANCER
RESEARCH
INSTITUTE

2018 ANNUAL REPORT

OUR MISSION:
SAVE MORE LIVES

by fueling the discovery and development of powerful immunotherapies for all types of cancer.

Established 65 years ago in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system's power to control and potentially cure all cancers.

To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field's leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers.

James P. Allison, Ph.D.
Director, CRI Scientific Advisory Council
2018 Nobel Prize Winner

Kristin Kleinhofer

leukemia survivor

After receiving intense chemotherapy that ultimately failed to keep her acute lymphoblastic leukemia (ALL) under control, Kristin enrolled in an immunotherapy clinical trial of chimeric antigen receptor T-cell (CAR T) therapy. Treatment with her reengineered immune cells worked and Kristin's leukemia disappeared. Today, more than three years later, she remains cancer free and is passionate about spreading her message of hope to others.

Watch Kristin's story at
cancerresearch.org/kristin

FROM CRI'S LEADERSHIP

Never before has there been more optimism that the answer to cancer is at last within reach. Immunotherapy is transforming cancer care and saving lives. The Cancer Research Institute (CRI) and the field of cancer immunology that it has supported for 65 years received important validation of immunotherapy's potential to treat all cancers when it was announced in October that CRI Scientific Advisory Council Director James P. Allison, Ph.D., will receive the 2018 Nobel Prize in Physiology or Medicine for his groundbreaking work in cancer immunotherapy.

This work has come to fruition after decades of CRI-funded basic and clinical research carried out by a global network of dedicated scientists, who persisted in the face of skepticism, bolstered by CRI's unwavering support and the conviction of its founders and scientific leadership that their work would one day unlock the immune system's potential to fight cancer. That day has come, at least for some patients, and CRI sees a path forward to lasting cures for more patients; research is the key.

This past year, CRI powered yet more promising laboratory and clinical research around the world with the ultimate aim of improving outcomes for all patients. With generous support from individual, corporate, and foundation donors, we were able to award $25 million in new research grants. These funds will be used to generate discovery along the entire research spectrum, from young postdoctoral fellows training under the mentorship of world-leading immunologists, to our translational research program that bridges the lab and the clinic, to clinical trials that bring cutting-edge combination therapies to cancer patients.

Since no one organization can solve the cancer problem alone, CRI seeks out strategic partnerships that leverage its 65 years of expertise while expanding its global footprint and carrying the impact of its work into new countries and patient populations. In 2018, we formed a multiyear collaboration with the Canadian Cancer Trials Group (CCTG) to develop and conduct immunotherapy trials with comprehensive trial designs to evaluate emerging therapies more efficiently within the ever-shifting immuno-oncology landscape. This latest collaboration complements our ongoing partnerships with Ludwig Cancer Research, the Parker Institute for Cancer Immunotherapy, and our growing list of biotech and pharmaceutical partners.

Immunotherapy's clinical successes have spurred unprecedented activity in cancer drug development, with an astounding number of novel therapies having entered the clinical development pipeline. FDA approvals of these treatments are coming at an accelerating pace, with more than 20 approvals in just the past five years. To chart these rapid advances, CRI published the first two of its immuno-oncology landscape reports in *Annals of Oncology* and *Nature Reviews Drug Discovery*, respectively. Cited numerous times in news articles and presented at major healthcare conferences, these reports attracted the attention of the Foundation for the National Institutes of Health, which has retained CRI as its source of immuno-oncology landscape data, which it hopes will help the foundation identify potential trials for the public-private Partnership for Accelerating Cancer Therapies (PACT), a program of the National Cancer Moonshot Initiative.

While CRI's primary focus has been and always will be funding the most promising science, we also seek to provide patients and caregivers who are exploring immunotherapy with clear and trustworthy information. In 2018, we expanded our Answer to Cancer Patient Education Program to include five Immunotherapy Patient Summits, held in Chicago, Houston, New York City, San Francisco, and Tampa. These events connect patients and caregivers to immunotherapy experts, who provide valuable insights into the latest research and treatment and what that means for cancer patients. Our Cancer Immunotherapy and You webinar series and Immunotherapy Patient Story video series attracted more than 1.3 million views online.

celebrating 65 years

During our sixth annual Cancer Immunotherapy Month in June, CRI activity generated more than 3.5 million impressions, bringing new exposure to CRI, cancer immunotherapy, and the urgent need to fund more research so that all patients can one day benefit from these treatments. We are especially grateful to all who participated in the month's events, including our corporate partners and their employees and our flourishing community of donors and supporters.

Donor support is never taken for granted. In 2018, we kept overhead costs low, so that 88 percent of expenses went directly to our charitable programs. In recognition of this commitment, CRI once again received the highest marks from charity watchdogs. With our sixth consecutive four-star rating from Charity Navigator, CRI ranks among the top six percent of all U.S. charities, according to a letter from Michael Thatcher, president and CEO of Charity Navigator.

As enthusiasm for cancer immunotherapy continues to grow, we are delighted that a new cadre of young professionals has volunteered to form the CRI Associate Board. This group of motivated brand ambassadors is committed to raising funds for and awareness of CRI and its mission.

We are also pleased to welcome to the Board of Trustees our newest members—Antonio C. Alvarez II, Kamini Banga, Michael J. Petrick, and Robert S. Stolar—who each bring a unique skill set, resources, and range of experiences that will augment the board's oversight and governance. We also wish to acknowledge the long and dedicated service of former trustee Maurice J. Cunniffe, who stepped down from the board earlier this year.

As we celebrate CRI's 65 years of leadership in cancer immunotherapy and the accomplishments of its thousands of funded scientists, we look to the horizon, seeking out the next great scientific questions with the same unrelenting pursuit that has served this organization well over the decades. Close as we are to realizing our vision of a world immune to cancer, we know there is yet more work to be done. With your continued support, we will get the job done.

PAUL C. SHIVERICK
Co-Chairman of the
Board of Trustees

ANDREW K. TSAI
Co-Chairman of the
Board of Trustees

JAMES P. ALLISON, PH.D.
Director of the
Scientific Advisory Council
2018 Nobel Prize Winner

JILL O'DONNELL-TORMEY, PH.D.
Chief Executive Officer
and Director of Scientific Affairs

POSTDOCTORAL FELLOWSHIPS

32 NEW FELLOWSHIPS

$5.5 MILLION AWARDED

POWERING THE NEXT GENERATION OF SCIENTIFIC LEADERS

The CRI Irvington Postdoctoral Fellowship Program provides training and financial support to the most promising young scientists working in the labs of world-leading cancer immunologists. CRI fellows are deepening our knowledge of the immune system, laying the foundation for tomorrow's immunotherapy breakthroughs. In the past year:

Tuo Li, Ph.D., of the University of Texas Southwestern Medical Center, developed a highly sensitive method to measure the levels of an important DNA damage-related protein, cGAMP, which has been shown to promote immune activity against cancer. With the novel tool he developed, Dr. Li was able to dynamically study cGAMP within cells and characterize the factors responsible for its decay, thus providing a foundation for the development of strategies to enhance its therapeutic effect.

Olivia Majer, Ph.D., of the University of California, Berkeley, determined how mutations in a certain pathway influence the activity of Toll-like receptors (TLRs) that can mediate cancer-promoting inflammation. In particular, she identified one mutation that disrupts a molecular "docking site" on the TLR7 molecule and causes TLR hyperactivity and autoimmune inflammation in mice. Moving forward, learning how to manipulate distinct aspects of TLR activation could enable improved approaches against both cancer and autoimmune diseases.

HARALD HARTWEGER, PH.D.

For a list of all 124 postdoctoral fellows active in FY2018, **click here.**

Davalyn Powell, Ph.D., of the University of Wisconsin-Madison, characterized the impact of immune cells called neutrophils in brain cancer. Using a zebrafish model of glioblastoma that enabled crucial visualization, Dr. Powell showed that these pro-inflammatory neutrophils are actively recruited to tumors during their development. Furthermore, she demonstrated that blocking this recruitment slowed the growth of tumor cells, highlighting an approach that could potentially be used to help patients in the clinic.

ROY L. MAUTE, PH.D.

IMPACT:
ENABLING IMMUNE CELLS TO "EAT" CANCER

Roy L. Maute, Ph.D., a CRI fellow at Stanford University from 2014–2015, published this year results of CRI-funded work he led that revealed a second "don't eat me!" signal that cancer cells can use to protect themselves against immune cells called macrophages. When this pathway was blocked, it improved macrophages' ability to eat—or phagocytose—cancer cells, both alone and in combination with another immunotherapy that is currently being evaluated in clinical trials.

To beat cancer, an understanding of the basic processes of the immune system is fundamental, as it is to cure all other diseases. The CRI Irvington Fellowship allows me to do exactly this: help lay a foundation for beating cancer."

— **HARALD HARTWEGER, PH.D.,** CRI Irvington Postdoctoral Fellow, The Rockefeller University

TRANSLATIONAL RESEARCH

12 NEW GRANTS

$2.4 MILLION AWARDED

BRIDGING BASIC AND CLINICAL SCIENCE

The Clinic and Laboratory Integration Program (CLIP) provides catalytic support over two years for scientists carrying out translational laboratory studies designed to answer new specific scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients.



PREVENTING CANCER IN ORGAN TRANSPLANT RECIPIENTS

John Carucci, M.D., Ph.D., Professor, Ronald O. Perelman Department of Dermatology; Director of Dermatologic Surgery; New York University Langone Medical Center, New York, NY

Organ transplant recipients take drugs to suppress the immune system so that their new organs are not rejected; this suppression, however, can also promote cancer development. Fortunately, Dr. Carucci found that blocking the activity of the JAK/STAT pathway reduces the growth of suppression-associated tumors in mice, thus providing a potential strategy through which cancer patients could be treated without compromising the tolerance of their transplants.

INTERFERING WITH REGULATORY T CELLS TO IMPROVE ANTI-TUMOR IMMUNITY

Alexander Y. Rudensky, Ph.D., Chair, Immunology Program, Sloan Kettering Institute; Director, Ludwig Center at Memorial Sloan Kettering; Professor of Immunology; Memorial Sloan Kettering Cancer Center, New York, NY

Regulatory T cells (Tregs), when found within tumors, can protect them by suppressing anti-tumor immune responses. To address this, Dr. Rudensky investigated the effects of an antibody targeting CCR4, a molecule expressed by Tregs. He found that in addition to decreasing circulating Tregs, this treatment increased the frequency and proliferation of anti-tumor "killer" T cells in patients' blood. This work highlights a potential strategy to make tumors more vulnerable to immune responses and immunotherapy.

TARGETING TUMORS WITH NANOPARTICLE-BASED VACCINES

Ferry A. Ossendorp, Ph.D., Professor, Molecular Vaccine Biology; Head, Tumor Immunology Group, Department of Immunohematology and Blood Transfusion; Leiden University Medical Centre, Leiden, The Netherlands

Every tumor is genetically unique, having accumulated different mutations. This makes vaccines that target a patient's unique tumor signature a potentially powerful treatment approach. To that end, Dr. Ossendorp optimized a liposome-based vaccine platform that could be loaded with tumor-specific markers and administered through the skin. These vaccines stimulated effective immune responses that eliminated both melanoma and HPV-associated tumors in mice and are currently being developed for use in humans.

JEFFREY RATHMELL, PH.D.

IMPACT:
JUICING UP CANCER-FIGHTING T CELLS WITH SUPER FUEL

CLIP Investigator **Jeffrey C. Rathmell, Ph.D.**, of Vanderbilt University, has found that sluggish "killer" T cells within kidney tumors improperly take up glucose—an essential energy source for cells—and had abnormal mitochondria that produced large amounts of reactive oxygen species (ROS), which can damage cells. He showed that T cell activation and function could be restored partially by either neutralizing these ROS or supplying an alternative fuel—pyruvate derived from breaking down glucose—providing important insights that could lead to metabolic strategies that complement immunotherapy.

For a list of all 45 CLIP Investigators active in FY2018, **click here.**

CLINICAL ACCELERATOR

$15 MILLION AWARDED

3 NEW TRIALS

COLLABORATION TO ACCELERATE CANCER CURES

The Anna-Maria Kellen Clinical Accelerator is a unique research partnership model created to develop, organize, and de-risk clinical study of next-generation combination cancer immunotherapies in collaboration with other nonprofits, academic institutions, and companies active in the immuno-oncology space. The program is powered by a venture philanthropy model designed to magnify donor impact while sustaining the program in perpetuity. Currently, eight clinical trials are open or enrolling patients, and two additional trials are planned to open in the coming year.

RECENTLY LAUNCHED CLINICAL TRIALS

A Clinical Accelerator study is evaluating the significance of a blood test or "liquid biopsy," designed to identify patients likely to respond to immunotherapy without the need for invasive surgical removal of tumor tissue. Another study will seek to determine the clinical importance of the volume of a specific type of immune cell within the tumor site, potentially identifying a new biomarker to predict patient responses as well as inform alternative strategies to improve treatment outcomes. A third study will test a variety of treatment combinations in patients with castration-resistant metastatic prostate cancer, a type of cancer that has proven elusive thus far to treatment with single immunotherapy agents.

NEW STRATEGIC PARTNERSHIP

In 2018, CRI expanded its global footprint by forming a multiyear partnership with the Canadian Cancer Trials Group (CCTG), a distinguished academic research group capable of rapid and efficient conduct of studies across an extensive trials network in Canada and internationally. The addition of CCTG to CRI's ongoing clinical partnerships significantly increases the Clinical Accelerator's bandwidth to carry out more trials and shortens the time between trial conception and patient enrollment. The first trials with CCTG will launch in the second half of 2018.

For more information on Clinical Accelerator trials, partnerships, and drug portfolio, visit **cancerresearch.org/accelerator**

VANESSA HUBBARD-LUCEY, PH.D., MBA

GROUNDBREAKING IO LANDSCAPE ANALYSES

The Clinical Accelerator team produced two first-of-their-kind reports detailing the significant growth and progress in immunotherapy drug development and the dramatic increase of cancer cell therapy trials in the clinical development pipeline. Both reports, published in the European Society for Medical Oncology's *Annals of Oncology* and *Nature Reviews Drug Discovery*, respectively, sparked important dialogue in the field among academic and industry stakeholders as well as patient advocates. The publications supported the decision of the Foundation for the National Institutes of Health (FNIH) to select CRI as its source of landscape intelligence in immuno-oncology. FNIH aims to use data and analyses from CRI to identify potential trials for the public-private Partnership for Accelerating Cancer Therapies (PACT), a program of the National Cancer Moonshot Initiative.

IMPACT:
NEW TRIAL LAUNCHED FOR COLORECTAL AND OVARIAN CANCER PATIENTS

CRI and its clinical partner Ludwig Cancer Research recently announced the launch of a new clinical trial testing a novel combination of virotherapy and immunotherapy to treat colorectal and ovarian cancers that do not respond to standard treatments. The Phase I/II trial is evaluating a combination of ONCOS-102, an experimental anti-tumor virotherapy from Norwegian biotech Targovax, with durvalumab (IMFINZI®), an anti-PD-L1 checkpoint inhibitor from AstraZeneca. The combination has the potential to stimulate robust and more effective anti-tumor immune responses, providing hope for patients with these hard-to-treat cancers.

"CRI's Clinical Accelerator program creates an independent space where philanthropic funding and clinical trial operation support facilitate the testing of agents from multiple companies in early phase, proof-of-concept clinical studies. Those studies are carried out by the leading cancer immunotherapy experts across multiple academic centers, positioning our organization as an ideal third-party partner to harness the expanding innovation in this space."

— **VANESSA HUBBARD-LUCEY, PH.D., MBA,** Director, CRI Venture Fund and Clinical Accelerator

IMPACT GRANTS

ADVANCING SCIENCE AND TECHNOLOGY TO SPEED INNOVATION

Through **Impact Grants**, CRI funds projects aimed at advancing defined scientific and technological goals and addressing major challenges that would otherwise limit progress in cancer immunotherapy research and drug development.

6 TUMOR IMMUNOLOGICAL SUBTYPES IDENTIFIED

$1.6 MILLION AWARDED

DREW PARDOLL, M.D., PH.D.

CHANGING HOW EARLY STAGE LUNG CANCER IS TREATED

Giving patients immunotherapy prior to surgical removal of non-metastatic lung cancer tumors delays and may prevent recurrence of the disease, a small clinical study funded by a CRI-SU2C Cancer Immunology Dream Team grant demonstrated earlier this year. If a larger study confirms the results, this approach may change the way patients with this disease are treated, with immunotherapy replacing chemotherapy prior to surgery. Presenting the data was Johns Hopkins University's **Drew Pardoll, M.D., Ph.D.**, a co-leader of the Dream Team, who shared preliminary results from the study, in which nine of twenty patients had major responses before surgery, while seventeen patients remained relapse-free after a year.

JUSTIN GUINNEY, PH.D.

ILYA SHMULEVICH, PH.D.

VESTEINN THORSSON, PH.D.

CATALOGUING CANCERS TO HELP CHART CURES

The CRI iAtlas, an open access database developed with CRI support by **Justin Guinney, Ph.D.**, of Sage Bionetworks, and **Ilya Shmulevich, Ph.D.**, and **Vesteinn Thorsson, Ph.D.**, of the Institute for Systems Biology, was launched in fiscal year 2018. Containing comprehensive data from 10,000 tumor samples across 33 cancer types gathered as part of the Pan-Cancer Atlas initiative, the final phase of The Cancer Genome Atlas, the CRI iAtlas allows oncologists and researchers to study interactions between tumors and the immune system. Already, it has enabled the identification of six tumor subtypes that are associated with distinct immune profiles and differential patient outcomes—regardless of their tumor type. As the CRI iAtlas data trove is further mined, it will likely spur more basic insights and guide the development of improved immunotherapy strategies for patients with all types of cancer.

THE RELATIONSHIP BETWEEN BACTERIA AND CANCER

CYNTHIA SEARS, M.D.

CRI-Fight Colorectal Cancer grantee **Cynthia Sears, M.D.**, of Johns Hopkins University, has made important insights into how the bacteria that live in our gut influence colorectal cancer. Specifically, she discovered that the type of bacteria found in the colon impacts immune activity in colorectal cancer patients, and that the biofilms that some bacteria form can promote inflammation as well as the development of colorectal cancer in mice. Moving forward, these insights could provide the foundation for improved therapeutic and preventive strategies for patients with the second leading cause of cancer death in women and the third for men.

For a list of all 13 Impact Grant recipients active in FY2018, **click here.**

DRUG DEVELOPMENT

HARNESSING INDUSTRY EXPERTISE

The **Cancer Immunotherapy Consortium (CIC)** is a think tank consisting of industry leaders from the cancer immunotherapy space. It provides a neutral platform whereon industry representatives work together and align on important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit.

BETTER DESIGN FOR LATE-STAGE IMMUNOTHERAPY TRIALS

Earlier this year, members of the Cancer Immunotherapy Consortium met in New York City to tackle problems linked to clinical trial endpoints—goals that determine whether a drug trial is successful or not—and the identification of biomarkers, which are biological or immune-related signals within a patient that may help predict responsiveness to immunotherapy.

IN SEARCH OF INTERMEDIATE ENDPOINTS

Common endpoints in pivotal clinical trials include progression-free survival, time to progression, objective response rate, and the most widely accepted success endpoint, overall survival. The CIC and other groups have worked in the past with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to help them better understand the differences in patient responses to immunotherapy compared to conventional treatments like chemotherapy or radiation. This effort resulted in the FDA modifying its approval criteria to accommodate how immunotherapies perform in the clinic.

FINDING NEEDLES IN HAYSTACKS

Finding meaningful biomarkers that predict patient responses to immunotherapy across all tumor types and subtypes is a Herculean effort. It requires an enormous pool of data that no one company or organization could assemble on its own. A significant collaborative effort is required in order to overcome this hurdle to achieving maximum benefit when treating patients with immunotherapy. Mindful of other biomarker projects currently underway, the CIC aims to leverage its membership's unique access to patient data to create a new resource to power insights leading to the identification of clinically relevant biomarkers.

CIC members meet to discuss collaboration strategies.

IMPACT:
INFORMING DRUG REGULATORS

Based on outcomes from its workshop earlier this year, the CIC now aims to work with the FDA to develop a set of intermediate endpoints that can be applied across all phases of clinical research. The goal is to improve the review process so that promising treatments are approved and reach patients sooner than current longer-term and costlier endpoints allow. Potential intermediate endpoints under discussion with the FDA include circulating tumor cell or DNA, PET scan for whole body tumor burden, tumor growth kinetics, or other novel endpoints tailored to specific cases based on biology.

To learn more about the Cancer Immunotherapy Consortium, visit **cancerresearch.org/cic**

SCIENTIFIC DIALOGUE

1,400 PARTICIPANTS

500 POSTERS PRESENTED

TRANSLATING SCIENCE INTO SURVIVAL

The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON) is a scientific meeting devoted to exploring the latest research in cancer immunotherapy. It attracts clinicians, scientists, drug developers, government regulators, and patient advocacy groups from all around the world.

Photo courtesy of the Association for Cancer Immunotherapy (CIMT)

In fiscal year 2018, CRI along with the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR), hosted the third CICON installment, held September 6–9, 2017, in Mainz, Germany.

Themed "Translating Science into Survival," the four-day conference provided a premier platform for experts in immunology and immunotherapy—including many of CRI's scientific advisors, clinical collaborators, and research fellows—to present the latest findings from the frontiers of the field.

Cornelis J.M. Melief, M.D., Ph.D.

To learn more about the conference, visit **cancerimmunotherapyconference.org**

Photo courtesy of the Association for Cancer Immunotherapy (CIMT)

Meeting topics included:

- personalized vaccines for patients
- biomarkers to predict immunotherapy responses
- novel immunotherapies and combinations to overcome resistance
- advances in cellular immunotherapies
- oncolytic viruses designed to target cancer
- bacterial influence on the immune system and immunotherapy's effectiveness

IMPACT:
PROVIDING A GLOBAL FORUM TO ADVANCE CANCER RESEARCH

The September 2017 conference brought together 1,400 scientists from 42 countries on 6 continents, who attended plenary lectures given by more than 50 expert speakers. The conference also showcased over 500 poster presentations of the latest basic and clinical immunotherapy research. The fourth conference in the series, occurring in fiscal year 2019, took place September 30–October 3, 2018, in New York City.

"At the CICON conference last year in Mainz, presentation of new scientific concepts went hand in hand with cutting-edge presentations of the most promising outcomes of clinical trials. No other conference in this field offers such a rich possibility for harmonious, productive, and above all exciting interactions between basic/translational scientists and clinicians."

— **CORNELIS J.M. MELIEF, M.D., PH.D.,** Chair, CICON 2017, Leiden University, The Netherlands

THOUGHT LEADERSHIP

29 EARNED MEDIA PLACEMENTS

8 EXECUTIVE APPEARANCES

A UNIQUE PERSPECTIVE IN A RAPIDLY EVOLVING FIELD

Jill O'Donnell-Tormey, Ph.D., (far left) participates in a Biotech Showcase panel on immunotherapy.

Today, any event focused on oncology research and development or latest advances in cancer treatment is certain to devote a greater part of its agenda to covering the exciting progress being made in cancer immunotherapy. As the dialogue continues to grow around this important topic, the Cancer Research Institute is increasingly called upon to provide unbiased expert insight at these events.

Over the past year, CRI spokespersons have participated in a number of high-profile conferences as keynote speakers and panelists, and have been featured in webinars on issues in global health and cancer immunotherapy research. Notable appearances include:

Forbes Global Health Roundtable
Challenges in Global Health
September 14, 2017, Webinar

Endpoints Breakfast Panel at JP Morgan Health
Where Is the Cancer R&D Revolution Headed?
January 9, 2018, San Francisco, CA

Biotech Showcase
IO on the Move: New Targets, New Trends, New Combinations
January 10, 2018, San Francisco, CA

Fortune Brainstorm Health
Weaponizing Your Body
March 19-20, 2018, Laguna Niguel, CA

Milken Institute Global Conference
Preserving the Promise of Cancer Immunotherapy
April 30, 2018, Los Angeles, CA

Precision Medicine World Congress
Assessing the I-O Landscape: Challenges and Opportunities in Cancer Research
June 7, 2018, Ann Arbor, MI

As cancer immunotherapy increasingly dominates news headlines, the media have also called upon CRI to provide comment on trends and challenges in the immuno-oncology field. Over the past year, CRI spokespersons have been quoted in 29 articles, including the following top-tier and trade publications:

BioCentury
BioPharma Dive
Bloomberg
Business Insider
Chemical & Engineering News
CNN
CURE
The Economist
Endpoints
Financial Times
Forbes
MarketWatch
MedCity News
S&P Global Market Intelligence
STAT
PharmaVoice
The Pink Sheet
The Wall Street Journal
The Washington Post

Immunotherapy is here to stay. It's not just a blip, it's not over-hyped—I think it's going to become the standard of care for many cancer types."

— **JILL O'DONNELL-TORMEY, PH.D.,** *Financial Times*, March 2018

PATIENT ENGAGEMENT

1,600 PATIENTS MATCHED TO TRIALS

1.3 MILLION EDUCATIONAL VIDEO VIEWS

BRINGING THE SCIENCE OF IMMUNOTHERAPY TO PATIENTS AND CAREGIVERS

Charles Drake, M.D., Ph.D., speaks at the CRI Immunotherapy Patient Summit in Houston earlier this year.

As a trusted source of information on cancer immunotherapy, CRI is committed to educating patients, caregivers, and broader audiences about the important developments in this rapidly evolving field of research and cancer treatment.

As part of our **Answer to Cancer Patient Education Program**, we offer a number of educational experiences for those who wish to learn more about cancer immunotherapy. These include online events, videos, downloadable information, summits designed to connect immunotherapy experts with patients and caregivers, and an Immunotherapy Clinical Trial Finder service along with additional resources.

To learn more, visit **cancerresearch.org/patients**

IMMUNOTHERAPY PATIENT SUMMIT SERIES

Learning about immunotherapy and clinical trials can be a lifesaving experience for patients considering their cancer treatment options. This past year, we held Immunotherapy Patient Summits in five U.S. markets including Chicago, Houston, New York City, San Francisco, and Tampa. During the free, half-day events, nearly 1,000 patients and caregivers heard directly from leading immunotherapy experts, who discussed the basics of cancer immunotherapy and the latest advances in the treatment of different cancers. A session devoted to demystifying clinical trials, a series of immunotherapy patient testimonials, and one-on-one appointments with clinical trial navigators provided attendees with information they need to advocate for their care. The series continues in fiscal year 2019 with events in Houston, New York City, San Diego, and San Francisco. A livestream webcast of the New York City summit was also made available free of charge and can be viewed on our YouTube channel.

IMMUNOTHERAPY CLINICAL TRIAL FINDER

Finding a clinical trial can be a daunting process. CRI provides an easy-to-use immunotherapy trial finder service that includes real-time interaction with Clinical Trial Navigators who are available to assist users in their search process. In 2018, more than 1,600 patients were matched to trials, bringing the total patients helped since we began offering this service in 2013 to over 11,000 patients.

CANCER IMMUNOTHERAPY AND YOU WEBINAR SERIES

Each month as part of our free webinar series for patients and caregivers, we invite immunotherapy experts to discuss important topics in cancer immunotherapy research and treatment. We also host patients treated with immunotherapy, who share their experiences with discovering immunotherapy and receiving it as part of their treatment. In 2018, webinar topics included five types of cancer and three types of immunotherapy as well as clinical trials, self-advocacy, and the field's progress over the past year. Our 2018 webinars have been viewed more than 223,000 times.

The summit was an amazing, amazing experience that taught me optimism and connected me to a larger community. Thank you."

— PATIENT SUMMIT ATTENDEE

PATIENT EDUCATION

Immunotherapy Patient Stories: CRI featured four patients with colorectal, leukemia, lung, and skin cancer, who shared their story from diagnosis to receiving immunotherapy as treatment and beyond.

Latest Immunotherapy News from ASCO: CRI's panel of experts discussed the latest cancer immunotherapy advances patients need to know that were featured at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO), the world's largest oncology conference. Participants included Charles G. Drake, M.D., Ph.D., of NewYork-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O'Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderated.

Talking to Your Oncologist about Cancer Immunotherapy: In this webinar for patients and caregivers, Ariella Chivil, a patient advocate, and Dr. Alexander M. Lesokhin, her oncologist at Memorial Sloan Kettering Cancer Center, discussed the nuances of communicating and informing both doctor and patient while receiving immunotherapy.

SOCIAL MEDIA

Wear White Day: A global call to action, our #WearWhite social media campaign urged the public to "Stand with Science" and support the search for immune-based cures by wearing white and sharing why they believe in cancer immunotherapy. Our supporters shared more than 1,000 photo posts on social media with the hashtag #WearWhite.

30 Breakthroughs in Immunotherapy: Every day in June, CRI posted a different scientific breakthrough based on CRI-funded research. These advancements highlighted CRI's 65 years in the field and our impact on the development of immunotherapy treatments of today and tomorrow.

CRI Associate Board at Bikes and Beers

IN-STUDIO CYCLING FUNDRAISERS

Pedal to the Medal CRI Cycling Challenge: Sixty employees from Mitsubishi UFJ Financial Group came together on June 21 at SWERVE Fitness Midtown in New York City, raising more than $25,000.

Bikes and Beers: On June 26, the CRI Associate Board hosted their event at SWERVE Fitness Flatiron in New York City with forty-eight cyclists in attendance, raising more than $87,000.

Thank you to our generous sponsors and supporters:

Sponsors: AbbVie, ACEA Biosciences, Adaptimmune, AstraZeneca, Bristol-Myers Squibb, Celgene, GSK, Immunotherapy Foundation, Inovio Pharmaceuticals, Juno Therapeutics, Merck, MUFG, Novartis, Regeneron, Sanofi Genzyme

Supporters: Agenus, American Association for Cancer Research, Association for Cancer Immunotherapy, Fibrolamellar Cancer Foundation, Fight Colorectal Cancer, Genentech, Israel Cancer Research Fund, Parker Institute for Cancer Immunotherapy, Replimune, Society for Immunotherapy of Cancer, Transcendent Planning, W2O Group

AWARDS & HONORS

RECOGNIZING EXCELLENCE

Each year, the Cancer Research Institute honors individuals and organizations that have made important contributions to the field of cancer immunotherapy.

THE WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN BASIC IMMUNOLOGY

Rafi Ahmed, Ph.D., Emory University, for his seminal work on immune memory as well as his definitive studies of the role of the PD-1 receptor in T cell exhaustion during chronic infection.

THE WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN TUMOR IMMUNOLOGY

Thomas F. Gajewski, M.D., Ph.D., University of Chicago, for his overall body of work that has enhanced our understanding of the interactions between tumors, immune cells, and other factors that play a role in the immune response to cancer.

THE FREDERICK W. ALT AWARD FOR NEW DISCOVERIES IN IMMUNOLOGY

Shannon J. Turley, Ph.D., Genentech, for her work on how stromal cells and immune cells influence each other in the context of inflammation, cancer, fibrosis, and response to immunotherapy.

THE OLIVER R. GRACE AWARD FOR DISTINGUISHED SERVICE IN ADVANCING CANCER RESEARCH

Bill Anderson, chief executive officer, Genentech, in recognition of his company's development of the first anti-PD-L1 therapy for first-line treatment of certain patients with bladder cancer, and of the company's support for CRI's research, conference, and patient education programs.

Bruce Ratner, philanthropist and New York City real estate developer, for his outstanding financial support of cancer research and treatment, his service to two of New York City's top cancer hospitals, and his ardent belief in the potential for cancer immunotherapy to radically transform cancer patient care.

THE AACR-CRI LLOYD J. OLD AWARD IN CANCER IMMUNOTHERAPY

Antoni Ribas, M.D., Ph.D., University of California, Los Angeles, for groundbreaking contributions to the successful development of checkpoint inhibitor immunotherapy for patients with metastatic melanoma.

Dr. Antoni Ribas, pictured with Dr. Jill O'Donnell-Tormey, receives the 2018 AACR-CRI Lloyd J. Old Award at the AACR Annual Meeting in Chicago.

1. Dr. Rafi Ahmed 2. Bill Anderson and Andrew Tsai 3. Drs. Jedd Wolchok and Tom Gajewski 4. Dr. Jill O'Donnell-Tormey and Bruce Ratner
5. Drs. Ellen Puré and Shannon Turley

SUPPORTED RESEARCH

104 INSTITUTIONS
11 COUNTRIES
56 NEW GRANTEES
18 U.S. STATES

FUNDING EXCELLENT SCIENCE THAT GETS RESULTS

In fiscal year 2018 (July 1, 2017, to June 30, 2018), the Cancer Research Institute awarded more than $21.6 million for cancer immunology research and immunotherapy clinical development.

An asterisk denotes grants newly awarded in fiscal year 2018. All others are active grants awarded in prior years.

CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM

Blood Center of Wisconsin, Milwaukee, WI
Ryan A. Zander, Ph.D.*
Identification of potent IL-21-producing T helper cell population that sustains cytotoxic T cell response during chronic viral infection and tumorigenesis

Boston Children's Hospital, Boston, MA
Sadeem Ahmad, Ph.D.
Non-canonical activation of the innate immune receptor MDA5 in immune disorder and cancer therapy

Zhaoqing Ba, Ph.D.
Mechanisms that mediate intra-locus and inter-locus regulation of V(D)J recombination at immunoglobulin light chain loci
Samuel and Ruth Engelberg Fellow

Ross W. Cheloha, Ph.D.
Study of B cell antigen receptor trafficking

Haiqiang Dai, Ph.D.*
Elucidation of feedback and other mechanisms of IgH allelic exclusion for production of therapeutic bispecific antibodies *in vivo*

Jun Hu, Ph.D.
Targeting Gasdermin D for potential therapeutic interventions
Margaret Dammann Eisner Fellow

Cheng-Sheng Lee, Ph.D.
Elucidating the mechanism and the impacts of RAG tracking

Mohammad Rashidian, Ph.D.
Non-invasive imaging of immune responses for early detection of cancer and to monitor immunotherapy

Heng Ru, Ph.D.
Structural and biochemical studies of the antigen receptor gene recombination machinery

Ying Zhang, Ph.D.*
Enhancing immunotherapy for triple-negative and HER2+ breast cancer with EpCAM aptamer-siRNA mediated gene knockdown

Liman Zhang, Ph.D.
Structural studies of NAIP/NLRC4 inflammasomes in immunity and cancer

Broad Institute of MIT and Harvard, Cambridge, MA
Le Cong, Ph.D.
Dissection of cellular states and transcriptional networks regulating innate immunity during tumorigenesis

Livnat Jerby, Ph.D.
Integrating CRISPR with single-cell RNA-sequencing to map the underlying circuits of immune evasion mechanisms in melanoma
The Hearst Foundations Fellow

Susan E. Klaeger, Ph.D.*
Immunopeptidomics for antigen discovery and prediction

California Institute of Technology, Pasadena, CA
Andrew I. Flyak, Ph.D.
The structural basis of HCV neutralization by broadly neutralizing human antibodies

Children's Hospital of Philadelphia, Philadelphia, PA
Nathan Roy, Ph.D.
Modulation of T cell trafficking by Crk adapter proteins

Columbia University Medical Center, New York, NY
Pranay Dogra, Ph.D.*
Impact of tissue location on antitumor activity of human NK cells

Dana-Farber Cancer Institute, Boston, MA
Adam N. R. Cartwright, Ph.D.
Systematic discovery of combination immunotherapy targets

Carina C. de Oliveira Mann, Ph.D.
Mechanism of STING activation of distinct immune signaling outputs
Eugene V. Weissman Fellow

Bo Hu, Ph.D.
Investigating the role of Prdm16 in the immunoregulation of tumorigenesis
Leonard Kahn Foundation Fellow

Hidetoshi Nakagawa, M.D., Ph.D.
Helios, Treg stability and cancer immunotherapy

Deng Pan, M.D., Ph.D.
Systematic discovery of immune modulators in tumor cells
Robertson Foundation Fellow

Emory University, Atlanta, GA
William H. Hudson, Ph.D.
Deciphering the role of lncRNAs in CD8+ T cell differentiation

The Francis Crick Institute, London, United Kingdom
Duncan Robert McKenzie, Ph.D.*
The molecular basis of epidermal cancer immunosurveillance

Fred Hutchinson Cancer Research Center, Seattle, WA
Valerie Phoebe O'Brien, Ph.D.*
Assessing Helicobacter pylori-mediated chronic inflammation and its contributions to stomach cancer progression

Shivani Srivastava, Ph.D.
An autochthonous solid tumor model to evaluate strategies for enhancing CAR-T cell therapy

Harvard Medical School, Boston, MA
Pavel Hanc, Ph.D.*
Investigating the neuroimmune interaction between nociceptive neurons and dendritic cells

Chaoran Li, Ph.D.
Differentiation and accumulation of adipose-tissue Tregs: Important players in the immunological control of metabolism and obesity-associated cancer

Martina Sassone-Corsi, Ph.D.*
Identifying bacterial molecules that induce gut immune responses and characterizing their protective potential against colitis-associated cancer.

Nisarg J. Shah, Ph.D.
Designing a synthetic bone marrow niche to overcome immunodeficiency
Gould Family Foundation Fellow

Alexandra M. Whiteley, Ph.D.
The role of Ubiquilin-1 in BCR-driven lymphoma proliferation

Harvard T.H. Chan School of Public Health, Boston, MA
Lior Lobel, Ph.D.
Identifying novel effectors of the gut microbiota that modulate cancer cells killing by CD8+ T cells using functional metagenomics

La Jolla Institute for Allergy and Immunology, La Jolla, CA
Christophe Pedros, Ph.D.
Control of regulatory T cell function by protein kinase C-eta (PKC): A novel target for cancer immunotherapy

Hyungseok Seo, Ph.D.*
Analysis of NFAT and Nr4a-mediated epigenetic reprogramming of tumor-infiltrating immune cell exhaustion
Donald J. Gogel Fellow

Massachusetts General Hospital, Boston, MA
Nilesh P. Talele, Ph.D.*
Re-engineering the obese tumor immune microenvironment to improve immunotherapy efficacy in pancreatic ductal adenocarcinoma

Massachusetts Institute of Technology, Cambridge, MA
Padmini Sushila Pillai, Ph.D.
Oral delivery of inflammation-targeting resolvin nanoparticles to treat IBD

Memorial Sloan Kettering Cancer Center, New York, NY
Simone Becattini, Ph.D.
Exploring colonization resistance against Listeria monocytogenes in cancer patients

Chun Chou, Ph.D.*
Origin and regulation of innate-like T cell responses in cancer

Zihou Deng, Ph.D.
Roles of macrophage subsets in tumorigenesis

Ariella Glasner, Ph.D.*
A study of mechanisms governing Foxp3-dependent and -independent gene expression in regulatory T cells using evolutionary distant mice

Wei Hu, Ph.D.
Tissue repair function of regulatory T cells during infection and cancer progression

Shun Li, Ph.D.*
Anti-tumor immunity unleashed by innate immune sensing of self-DNA
Lloyd J. Old Fellow

Alejandra Mendoza, Ph.D.
Role of "non-immune" functions of regulatory T cells in tissue homeostasis and cancer development
Bristol-Myers Squibb Fellow

Fella Tamzalit, Ph.D.
The role of the centrosome in cytotoxic T cell function
Lloyd J. Old Fellow

National Cancer Institute, NIH, Bethesda, MD
Marie Anne Vetizou, Ph.D.*
Targeting microbiota for improving cancer immunotherapy

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
Michael G. Constantinides, Ph.D.
Role of the microbiome in lung cancer

Ivan Vujkovic-Cvijin, Ph.D.
Identifying novel microbiome-based immunotherapeutics for melanoma

Geoffrey Lovely, Ph.D.
Watching RAG recombinase assembly on the IgH locus and off-target assembly in live pro-B cells

The Netherlands Cancer Institute, Amsterdam, The Netherlands
Chong Sun, Ph.D.
Unraveling the biology of CMTM6, a novel regulator of PD-L1 identified through genome-wide genetic screening

New York University Medical Center, New York, NY
Priya Darshinee A. Issuree, Ph.D.
Roles of Runx3 in inflammatory T cells and colorectal cancer

Ranit Kedmi, Ph.D.
Antigen presenting cells as coordinators of T cell responses to gut microbiota
Robertson Foundation Fellow

Hao Xu, Ph.D.
Identification of the RORt ligands, protein complexes and targeting signals involved in Th17 cell-mediated homeostasis and pathogenesis

Northwestern University, Evanston, IL
Elizabeth M. Steinert, Ph.D.
Mitochondrial respiration in CD8 T cell-mediated immune responses to solid tumors

The Rockefeller University, New York, NY
Rony Dahan, Ph.D.
Enhancing monoclonal antibody-mediated immune responses within the tumor microenvironment

Jonatan Ersching, Ph.D.
Molecular control of B cell proliferation in germinal centers
The Hearst Foundations Fellow

Harald Hartweger, Ph.D.
The effect of replicative stresses on the genesis of chromosome translocations

Qiang Li, Ph.D.
Chemical biology of anti-inflammatory lipids

Yen-Chih Wang, Ph.D.
Chemical biology of microbiota protection against gastrointestinal cancer

Seattle Children's Research Institute, Seattle, WA
Joseph K. Cheng, Ph.D.*
Development and characterization of a humanized synthetic notch receptor platform to regulate chimeric antigen receptor T cell immunotherapies in a solid tumor model

Stanford University, Stanford, CA
Liang Chen, M.D., Ph.D.
Systemic identification of melanoma-specific antigens that can elicit cytotoxic T cell responses following anti-PD1 immunotherapy
Robertson Foundation Fellow

Polimyr Caesar Dave Pelisco Dingal, Ph.D.
Programmable cancer recognition using a chimeric system of notch and CRISPR

Monica M. Olcina, Ph.D.
Innate immunity and cancer: Targeting the complement system to improve treatment response

Ansuman T. Satpathy, M.D., Ph.D.
Single cell epigenomics in cancer immunity and immunotherapy

Qian Yin, Ph.D.
Activation of endogenous anergic self-specific CD8+ T cells by polymeric nanoparticles for enhanced cancer immunotherapy
Lloyd J. Old Fellow

Yu Zhu, Ph.D.*
Targeting notch signaling in tumor endothelial stem cells to normalize tumor vasculature and improve anti-tumor immunity and immunotherapies

Uniformed Services University of the Health Sciences, Rockville, MD
Maria Kathleen Traver, Ph.D.
Macroautophagic control of lymphocyte activation and proliferation

University Health Network, Toronto, Canada
Christian Bassi, Ph.D.
Role of HMGB1 in breast cancer resistance to chemotherapy

Julie Leca, Ph.D.
Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases

University of California, Berkeley, Berkeley, CA
Rutger David Luteijn, Ph.D.
Inflammatory pathways in senescence-induced tumor formation

Olivia Majer, Ph.D.
Dysregulated Toll-like receptor responses as an oncogenic driver

Kathleen Pestal, Ph.D.
The regulation of apoptotic cell-clearance identity in tissue-resident macrophages

University of California, San Diego, La Jolla, CA
Sascha Hans Duttke, Ph.D.
Reprogramming macrophage phenotypes during immunosurveillance and neoplastic progression

Claudia Han, Ph.D.
Epigenomic modulation of microglia function in homeostasis and gliomas

Yunlong Zhao, Ph.D.*
Investigating the roles of cis-interactions in regulating the PD-1 pathway

University of California, San Francisco, San Francisco, CA
Oscar A. Aguilar, Ph.D.*
The role of Fcg receptors in NK-mediated immunity against cancer and virus infection

Kevin C. Barry, Ph.D.
Interrogation of immune responses to fibrolamellar hepatocellular carcinoma
CRI Fibrolamellar Cancer Foundation Fellow

En Cai, Ph.D.
Understanding the fundamental processes of T cell immunity through high precision 3D dynamic imaging of antigen recognition
Robertson Foundation Fellow

Rogelio Antonio Hernandez-Lopez, Ph.D.
Engineering antigen density sensors for T cell immunotherapy
Merck Fellow

Aileen Li, Ph.D.*
Synthetic modulation of the tumor microenvironment
Merck Fellow

Adam Jacob Litterman, Ph.D.*
A global map of mRNA regulatory elements in CD8+ T cells

Dan Liu, Ph.D.
LSC and its G protein coupling signaling as regulators of dendritic cell maintenance and function in immune responses
AstraZeneca Fellow

Megan K. Ruhland, Ph.D.
Mechanisms of peripheral self-tolerance contribute to immune tolerance to cancer

Avishai Shemesh, Ph.D.*
Engineering CAR NK cells for antigen-dependent autocrine expansion

University of Chicago, Chicago, IL
Kristof Nolan, Ph.D.*
Structure and function of Human Leukocyte Antigen-F in gynecologic cancers

University of Minnesota, Minneapolis, MN
Henrique Borges da Silva, Ph.D.*
Harnessing CD8+ T cell antitumor responses by manipulating extracellular ATP signaling
Paul C. Shiverick Fellow

Pamela C. Rosato, Ph.D.
Harnessing tissue resident memory T cells to combat solid tumors

University of Pennsylvania, Philadelphia, PA
Mohamed Abdel Hakeem, Ph.D.
Reprogramming of exhausted T lymphocytes following cure of chronic viral infection: Implications for immunotherapy

Josephine R. Giles, Ph.D.*
Defining the transcriptomic and epigenetic reprogramming of human tumor-infiltrating CD8 T cells after PD-1 blockade

Anthony Tsai-Chieh Phan, Ph.D.
Redefining the T cell-intrinsic role of IL-27 signaling in the tumor microenvironment
Robertson Foundation Fellow

The University of Texas MD Anderson Cancer Center, Houston, TX
Mr. Peiwen Chen, Ph.D.*
Mechanism and therapeutic potential of PTEN-regulated macrophages in glioblastoma

Ka Ho Stephen Mok, Ph.D.
Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation

The University of Texas Southwestern Medical Center, Dallas, TX
Jonggul John Kim, Ph.D.*
Manipulation of T-cell receptor signaling by phase separation of signaling molecules

Tuo Li, Ph.D.
Roles of mammalian cyclic dinucleotide signaling in cancer therapies

Xiaojun Tan, Ph.D.
Phosphoinositide regulation of STING trafficking and cancer immunity

University of Virginia Health System, Charlottesville, VA
Justin S. A. Perry, Ph.D.*
Regulation of phagocyte physiology during tumor cell clearance
The Mark Foundation for Cancer Research Fellow

University of Washington, Seattle, WA
Marc Joseph Lajoie, Ph.D.
Protein nanoparticles to elicit defined T cell response against cancer cells

Kevin Michael Sullivan, M.D.
T cell immunotherapy in fibrolamellar cancer
CRI Fibrolamellar Cancer Foundation Fellow

Daan Vorselen, Ph.D.*
Role of mechanics in phagocytic clearance of cancer cell mimics

University of Wisconsin-Madison, Madison, WI
Sofia L. Novais de Oliveira, Ph.D.
The role of the innate immune system in fibrolamellar hepatocellular carcinoma (FL-HCC): FHL2 as a putative molecular target
CRI Fibrolamellar Cancer Foundation Fellow

Davalyn Renee Powell, Ph.D.
The role of neutrophils and CXCL8-CXCR1/2 signaling in glioblastoma cell invasion

Vanderbilt University, Nashville, TN
Katy Beckermann, M.D., Ph.D.
Metabolic barriers to T cell function and immunotherapy in renal cell carcinoma
Merck Fellow

Washington University School of Medicine, St. Louis, MO
Jennifer Kaoru Bando, Ph.D.
Immune modulation of dormant skin tumor development and persistence

Danielle M Lussier, Ph.D.
Broadening the cancer immunotherapeutic window via subclinical irradiation
Robertson Foundation Fellow

Weill Cornell Medicine, New York, NY
Chang-Suk Chae, Ph.D.
Incessant ER stress responses promote dendritic cell dysfunction in ovarian cancer
Dr. Keith Landesman Memorial Fellow

Li Zhang, Ph.D.
Type I interferon control of macrophage cell death
Robertson Foundation Fellow

Weizman Institute of Science, Rehovot, Israel
Ido Yofe, Ph.D.*
Single-cell analysis of the tumor-immune ecosystem in human cancers

Whitehead Institute for Biomedical Research, Cambridge, MA
Yang Eric Guo, Ph.D.
Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune system

Kehui Xiang, Ph.D.
Investigate the importance and mechanism of poly(A) tail length-mediated translational control in different immune cells

Yale University, New Haven, CT
Najla Arshad, Ph.D.
The effect of tumor-associated mutant calreticulin on antigen presentation and tumorigenesis

Will Harrison Bailis, Ph.D.
Identification and characterization of immune escape mechanisms in leukemia

Ruth A. Franklin, Ph.D.
The role of macrophages in tissue homeostasis and tumor progression
Donald J. Gogel Fellow

Jun Young Hong, Ph.D.*
Developmental programming of T cell immunity and cancer susceptibility
Bristol-Myers Squibb Fellow

Chun-Chieh Hsu, Ph.D.*
Regulation of translation by the interferon-induced antiviral protein viperin

Guangchuan Wang, Ph.D.
Genetic dissection of PD-1 pathway immune checkpoint blockade in liver cancer

CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP)

Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Lydia Lynch, Ph.D.
The relationship between metformin, obesity and cancer immunotherapy success

Case Western Reserve University, Cleveland, OH
David Wald, M.D., Ph.D.*
Targeting TGF/GSK3 to enhance NK cell therapy for colon cancer

City of Hope National Medical Center, Duarte, CA
Markus Muschen, M.D., Ph.D.
Targeted hyperactivation of B cell receptor signaling to amplify therapeutic responses to CART19-treatment

Dana-Farber Cancer Institute, Boston, MA
Philip J. Kranzusch, Ph.D.
Controlling activation of STING responses in cancer immunotherapy

Allison Frances O'Neill, M.D.*
The role of checkpoint inhibition in pediatric hepatocellular carcinoma: Clinical efficacy and biologic correlates

Foundation for Applied Medical Research, FIMA, Pamplona, Spain
Ignacio Melero, M.D., Ph.D.
Functional expression of PD-L1 on professional cross-priming denritic cells

Fred Hutchinson Cancer Research Center, Seattle, WA
Edus H. Warren, M.D., Ph.D.*
A platform for single-cell functional characterization of tumor infiltrating lymphocytes from renal cell carcinoma

Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III, Madrid, Spain
Manuel Valiente, Ph.D.*
Brain-specific strategies to improve responses to immunotherapy

Icahn School of Medicine at Mount Sinai New York, NY
Nina Bhardwaj, M.D., Ph.D.
Analysis of immune responses induced by *in situ*, autologous therapeutic vaccination against solid cancers with intratumoral Hiltonol (Poly-ICLC)

Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
Antoni Celià-Terrassa, PhD*
LCOR orchestrates the differential IFN-alpha response and immunological properties of triple-negative breast cancer stem cells.

Leiden University Medical Center, Leiden, The Netherlands
Ferry A. Ossendorp, Ph.D.
Novel vaccine nanoformulations for clinical mutanome-based cancer immunotherapy

Massachusetts General Hospital, Boston, MA
Shadmehr Demehri, M.D., Ph.D.
CD4+ T cell immunity against early skin carcinogenesis

Andrew D. Luster, M.D., Ph.D.
Targeting the CXCR3 chemokine system to improve anti-PD-1 immunotherapy

Medical College of Wisconsin, Milwaukee, WI
Li Wang, Ph.D.
Defining the role of a novel T cell-regulatory receptor in the development of anti-tumor immunity

Medical University of South Carolina, Charleston, SC
Mark P. Rubinstein, Ph.D.
Generating human tumor-reactive T cells with high levels of IL-2Ra for adoptive T cell therapy



Memorial Sloan Kettering Cancer Center, New York, NY
Alexander Y. Rudensky, Ph.D.
Immunoregulatory correlates of a phase I/II study of mogamulizumab (KW-0761) in subjects with advanced and/or metastatic solid tumors
Genentech CLIP Investigator

New York University Medical Center, New York, NY
John Carucci, M.D., Ph.D.
Targeting the immune system to treat aggressive squamous cell carcinoma

Northwestern University, Evanston, IL
Derek Alan Wainwright, Ph.D.
IDO1 in glioblastoma: Translating work from mouse to man
Wade F. B. Thompson CLIP Investigator

Oregon Health & Science University, Portland, OR
Rajan Kulkarni, M.D., Ph.D.*
Elucidating the molecular basis of skin-directed irAEs

Amanda W. Lund, Ph.D.
FasL expressing lymphatic vessels in melanoma

Ottawa Hospital Research Institute, Ottawa, Canada
John C. Bell, Ph.D.
Bio-engineering an oncolytic vaccinia virus to augment the anti-tumor immune response in human cancers

QIMR Berghofer Medical Research Institute, Brisbane, Australia
Mark John Smyth, Ph.D., FAHMS
Targeting NK cell differentiation in cancer

The Rockefeller University, New York, NY
Jeffrey V. Ravetch, M.D., Ph.D.*
A proof-of-concept clinical study testing an Fc-optimized anti-CD40 agonist antibody in patients with cancer

Salk Institute, La Jolla, CA
Susan M. Kaech, Ph.D.
Elucidating cellular and genetic factors associated with tumor resistance to immunotherapies

Universidad Autónoma de Madrid, Madrid, Spain
Bruno Sainz, Jr., Ph.D.
Role of the innate immune system in promoting cancer stem cells

Universita di Verona, Verona, Italy
Vincenzo Bronte, Ph.D.
Neutralizing human arginase to enhance cancer immunotherapy

Universite de Lausanne, Lausanne, Switzerland
Ping-Chih Ho, Ph.D.
UCP2-regulated immunostimulatory shift of the tumor microenvironment in melanomas

Daniel E. Speiser, M.D.
Identification and validation of new targets for cancer immunotherapy in "exhausted" anti-cancer CD8 T cells from mice and humans

University Health Network, Toronto, Canada
Tak W. Mak, Ph.D., D.Sc., FRSC.
Evaluating the role of Toso-mediated inflammation in anti-tumor responses

University of Bordeaux, Bordeaux, France
Vanja Sisirak, Ph.D*
In vivo study of mechanisms that regulate tumor-derived DNA immunogenicity during the process of cancer immunosurveillance

University of California, Los Angeles, Los Angeles, CA
Prof. Hilary Ann Coller, Ph.D.
Testing stromal autophagy as a predictor of melanoma immunity

Prof. Robert M. Prins, Ph.D.*
Elevated TIL accumulation, with clonal TCR expansion and inflammatory tumor gene expression, predicts clinical benefit of PD-1 blockade in patients with recurrent glioblastoma
Wade F. B. Thompson CLIP Investigator

University of Chicago, Chicago, IL
Stephen J. Kron, M.D., Ph.D.
Radiation-enhanced delivery of checkpoint
blockade antibodies

The University of Melbourne, Melbourne, Australia
Jose A. Villadangos, Ph.D.
Characterization and prevention of "Stunning," a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer

University of Texas Health Science Center at San Antonio, San Antonio, TX
Nu Zhang, Ph.D.*
The cellular mechanisms controlling PD-1 blockade-responding CD8 T cells



The University of Texas MD Anderson Cancer Center, Houston, TX
Michael A. Curran, Ph.D.
Hypoxia drives tumor immune suppression and immunotherapy resistance

University of Virginia Health System, Charlottesville, VA
Craig L. Slingluff Jr., M.D.
Retention integrins: induction and function on cancer-reactive T lymphocytes
Wade F. B. Thompson CLIP Investigator

Craig L. Slingluff Jr., M.D.
Barrier molecules and their impact on T cell infiltration in melanoma

University of Washington, Seattle, WA
Andrew Oberst, Ph.D.*
Inducing immunogenic cell death to improve cancer immunotherapy
Wade F. B. Thompson CLIP Investigator

Walter and Eliza Hall Institute of Medical Research, Parkville Victoria, Australia
Nicholas David Huntington, Ph.D.
Development of a checkpoint inhibitor that targets the intracellular protein CIS to enhance NK cell anti-tumour immunity

Washington University School of Medicine, St. Louis, MO
Gavin Peter Dunn, M.D., Ph.D.
Monitoring the anti-tumor immune response in glioblastoma patients treated with a personalized neoepitope vaccine

Weill Cornell Medicine, New York, NY
Niroshana Anandasabapathy, M.D., Ph.D.
Actioning a newly-defined target of peripheral tumor-immune surveillance in dendritic cells

Juan R. Cubillos-Ruiz, Ph.D.
Targeting LPA sensors in the tumor microenvironment to enhance ovarian cancer immunotherapies
Wade F. B. Thompson CLIP Investigator

Gregory F. Sonnenberg, Ph.D.*
Modulating host-microbiota interactions to improve cancer immunotherapies
Wade F. B. Thompson CLIP Investigator

Yale University, New Haven, CT
Prof. Sidi Chen, Ph.D.
Systematic identification of druggable targets for enhancement of PD-1 checkpoint blockade therapy in melanoma

COORDINATED CANCER INITIATIVES

University of Toulouse, Villejuif, France
Maha Ayyoub, Pharm.D., Ph.D.
Role of the gut microbiota in the ontogeny and homeostasis of regulatory CD4 T cells and in their alteration along immune responses to ovarian cancer

CLINICAL ACCELERATOR

Clinical Strategy Team Grants

The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy
Team Leads: Nina Bhardwaj, M.D., Ph.D.,
Sacha Gnjatic, Ph.D.
Investigators: Eric Schadt, Ph.D., Rachel Sabado, Ph.D., Matthew D. Galsky, M.D., Icahn School of Medicine at Mount Sinai, New York, NY

Targeting the tumor immune microenvironment to enhance immune-stimulating effects of chemoradiotherapy
Team Lead: Andrew Sikora, M.D., Ph.D., Baylor College of Medicine, Houston, TX
Investigators: Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Christine Chung, M.D., Moffitt Cancer Center, Tampa, FL; Nham Tran, Ph.D., University of Technology, Sydney, Australia; Cornelis J.M. Melief, M.D., Ph.D., Leiden University, Leiden, The Netherlands

Enhancing T-cell homing to solid cancers by stimulating proper chemokines
Team Leads: Hideho Okada, M.D., Ph.D., Lawrence Fong, M.D., University of California, San Francisco, San Francisco, CA
Investigators: Robert P. Edwards, M.D., Pawel Kalinski, Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA; Kunle Odunsi, M.D., Ph.D., Roswell Park Comprehensive Cancer Center, Buffalo, NY

Immunotherapeutic targeting cell surface neoantigen SAS1B (Ovastacin, ASTL)
Team Lead: Craig L. Slingluff Jr., M.D.
Investigators: Victor Engelhard, Ph.D., Timothy Bullock, Ph.D., Mark Kester, Ph.D., University of Virginia Health System, Charlottesville, VA; Jamal Zweit, Ph.D., Virginia Commonwealth University, Richmond, VA

Clinical Trials Funded

An open label, phase 1 study of TESLA-001, with checkpoint inhibitor, in patients with metastatic cancer
Study Chairs: Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Gavin Dunn, M.D., Ph.D., Washington University School of Medicine, St. Louis, MO

Multi-center phase 1 study of NY-ESO-1 vaccine in combination with ipilimumab in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated
Study Chairs: Jedd D. Wolchok, M.D., Ph.D., Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
Lead Investigators: Jonathan S. Cebon, Ph.D., FRACP, Austin Health/Ludwig Cancer Research, Melbourne, Australia; Craig E. Devoe, M.D., North Shore LIJ, North Shore University Hospital, Manhasset, NY; Philip Friedlander, M.D., Icahn School of Medicine at Mount Sinai, New York, NY; Michael A. Postow, M.D., Memorial Sloan Kettering Cancer Center, New York, NY; Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA; Hussein Tawbi, M.D., Ph.D., University of Pittsburgh Cancer Institute, Pittsburgh, PA

A phase 1 study to assess safety and tolerability of tremelimumab in combination with MEDI4736, administered after high dose chemotherapy and autologous stem cell transplant in subjects with multiple myeloma who are at high risk of relapse
Study Chairs: Hearn Jay Cho, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase 1 study to evaluate the safety and tolerability of anti-PD-L1, MEDI4736, in combination with tremelimumab in subjects with advanced solid tumors
Study Chairs: Jedd D. Wolchok, M.D., Ph.D., Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
Lead Investigators: Kunle Odunsi, M.D., Ph.D., Roswell Park Comprehensive Cancer Center, Buffalo, NY; Patrick Ott, M.D., Dana-Farber Cancer Institute, Boston, MA; Patrick Dillon M.D., University of Virginia Health System, Charlottesville, VA; Mario Sznol, M.D., Yale University, New Haven, CT; Reva Schneider, M.D., Mary Crowley Cancer Research, Dallas, TX

A phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies
Study Chair: Dmitriy Zamarin, M.D., Memorial Sloan Kettering Cancer Center, New York NY
Lead Investigators: Kunle Odunsi, M.D., Ph.D., Roswell Park Comprehensive Cancer Center, Buffalo, NY; Brian Slomovitz, M.D., University of Miami School of Medicine, Miami, FL; Linda Duska, M.D., University of Virginia Health System, Charlottesville, VA; John Neumanitis, M.D., University of Toledo Medical Center, Toledo, OH

A phase 1/2 study of ALK inhibitor, ensartinib (X-396), and anti-PD-L1, durvalumab (MEDI4736), in subjects with ALK-rearranged (ALK-positive) non-small cell lung cancer
Study Chair: Leena Gandhi, M.D., Ph.D., NYU Langone Medical Center, New York NY
Lead Investigator: Jhanelle Gray, M.D., Moffitt Cancer Center, Tampa, FL
A phase 1 study of combination immunotherapy and mRNA vaccine in subjects with non-small cell lung cancer
Lead Investigator: Joshua Sabari, M.D., NYU Langone Medical Center, New York NY

A phase 1/2 study of *in situ* vaccination with checkpoint antibodies tremelimumab and MEDI4736 plus the toll-like receptor agonist PolyICLC in subjects with advanced, measurable, biopsy-accessible cancers
Study Chairs: Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Craig L. Slingluff Jr., M.D., University of Virginia Health System, Charlottesville, VA
Lead Investigators: Matteusz Opyrchal, M.D., Roswell Park Comprehensive Cancer Center, Buffalo, NY; Michael Lowe, M.D., Emory University School of Medicine, Atlanta, GA; Ahmad Tarhini M.D., Cleveland Clinic, Cleveland, OH; Keisuke Shirai M.D., Dartmouth-Hitchcock, Lebanon, NH

A phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma
Study Chair: David Allen Reardon, M.D., Dana-Farber Cancer Institute, Boston MA
Lead Investigators: Hui Gan, M.D., Austin Hospital, Melbourne, Australia; Thomas Kaley, M.D., Memorial Sloan Kettering Cancer Center, New York, NY; Tim Cloughesy, M.D., University of California, Los Angeles School of Medicine, Los Angeles, CA; Michael Lim, M.D., Johns Hopkins University, Baltimore, MD; Jennifer Clarke, M.D., University of California, Los Angeles School of Medicine, Los Angeles, CA; Gavin Dunn, M.D., Ph.D., Washington University School of Medicine, St. Louis, MO; Jorg Dietrich, M.D., Massachusetts General Hospital, Boston, MA

A phase 1/2 study of chemoimmunotherapy with anti-PD-L1 antibody durvalumab/MEDI4736 in subjects with recurrent, platinum-resistant ovarian cancer for whom PLD is indicated
Study Chair: George Coukos, M.D., Ph.D., Ludwig Centre for Cancer Research of the University of Lausanne, Lausanne Switzerland
Lead Investigators: Roisin O'Cearbhail, M.D., Memorial Sloan Kettering Cancer Center, New York, NY; Anita Wolfer M.D., Ph.D., Lausanne University Hospital, Lausanne, Switzerland; Bradley Monk, M.D., Arizona Oncology, Phoenix, AZ; David O'Malley, M.D., Ohio State University Wexner Medical Center, Columbus, OH; Paul DiSilvestro, M.D., Woman and Infants Hospital, Providence, RI

Open-label, multicenter, phase 1b/2 clinical study to evaluate the safety and efficacy of CD40 agonistic monoclonal antibody (APX005M) administered together with gemcitabine and nab-paclitaxel with or without PD-1 blocking antibody (nivolumab) in patients with previously untreated metastatic pancreatic adenocarcinoma
Study Chair: Robert H. Vonderheide, M.D., D.Phil., Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Lead Investigators: Mark O'Hara, M.D., Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Eileen O'Reilly, M.D., Memorial Sloan Kettering Cancer Center, New York, NY; Gauri R. Varadhachary, M.D., The University of Texas MD Anderson Cancer Center, Houston, TX; Zev Wainberg, M.D., University of California, Los Angeles School of Medicine, Los Angeles, CA; Andrew Ko, M.D., University of California, San Francisco, San Francisco, CA; George Fischer, M.D., Stanford University School of Medicine, Stanford, CA;
Osama Rahma, M.D., Dana-Farber Cancer Institute, Boston, MA

Multicenter, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)*
Study Chair: Lawrence Fong, M.D., University of California, San Francisco, San Francisco, CA Lead Investigators: Matt Galsky M.D., Icahn School of Medicine at Mount Sinai, New York, NY; Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Karen Autio, M.D., MSc, Memorial Sloan Kettering Cancer Center, New York, NY

Nivolumab ipilimumab in patients with hypermutated cancers detected in blood (NIMBLe)*
Study Chair: Naiyer Rizvi, M.D., Columbia University Medical Center, New York, NY
Lead Investigators: Tim Chan, M.D., Ph.D, Memorial Sloan Kettering Cancer Center, New York, NY; Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY; Jeffrey Weber, M.D., Ph.D, NYU Langone Medical Center, New York NY; Patricia Tang, M.D., Tom Baker Cancer Center, Alberta Health Services, Calgary, Canada; Michael Vickers, M.D., MPH, The Ottawa Hospital, Ontario, Canada; Holger Hirte, M.D., Juravinski Cancer Center, Ontario, Canada; Neesha Dhani, M.D., Princess Margaret Hospital, Toronto, Canada; Stephen Burns, M.D., British Columbia Cancer Agency

An exploratory study of nivolumab with or without ipilimumab according to the percentage of tumoral CD8 cells in participants with advanced metastatic cancer*
Study Chair: Padmanee Sharma, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX
Lead Investigators: Stephen Hodi, M.D., Dana-Farber Cancer Institute, Boston, MA; Alexandra Drakaki, M.D., University of California, Los Angeles, Los Angeles, CA; Danny Khalil, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY; Lawrence Fong, M.D., University of California, San Francisco, San Francisco, CA; Shivaani Kumar, M.D., FACP, Stanford University, Stanford, CA

Correlative and Laboratory Studies

Contribution of tumor antigen-specific adaptive immunity to responsiveness to immune checkpoint blockade
Maha Ayyoub, Pharm.D., Ph.D.
University of Toulouse, Toulouse, France

Reagent Production

Production of NY-ESO-1 overlapping peptides for use in a variety of trials
Polypeptide Laboratories, San Diego, CA

IMPACT GRANTS

American Association for Cancer Research
Philadelphia, PA*
Collaboration on *Cancer Immunology Research*

Justin Guinney, Ph.D.*
Sage Bionetworks, Seattle, WA
The Pan-Cancer Immune Atlas: Platform for immuno-oncology research and data sharing

Predoctoral Emphasis Pathway in Tumor Immunology
Johns Hopkins University School of Medicine
Baltimore, MD
Program Leader: Drew M. Pardoll, M.D., Ph.D.

Lloyd J. Old Advanced Training Program in Immunology and Oncoimmunology
Lomonosov Moscow State University,
Moscow, Russia
Program Leader: Sergei A. Nedospasov, Ph.D., D.Sc.*

Technology Impact Awards

Brian D. Brown, Ph.D.*
Icahn School of Medicine at Mount Sinai,
New York, NY
Development of a novel technology for cancer immunology target discovery

Dongeun Dan Huh, Ph.D.
University of Pennsylvania, Philadelphia, PA
A microengineered biomimetic model of tumor-immune cell interactions

Hyun Jung Kim, Ph.D.*
University of Texas at Austin, Austin, TX
A pathomimetic colorectal cancer-on-a-chip for unveiling the role of gut microbiome on cancer immunotherapy

Ashish Kulkarni, Ph.D.*
University of Massachusetts, Amherst, Amherst, MA
Nanoscale platform technology for monitoring immunotherapeutic responses

Partnership Grants

James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, and Antoni Ribas, M.D., Ph.D., UCLA Medical Center, Los Angeles, CA
Cancer Immunology Translational Research Dream Team: Immunologic checkpoint blockade and adoptive T cell transfer in cancer therapy
In partnership with the Entertainment Industry Foundation/ Stand Up To Cancer

Timothy N.J. Bullock, Ph.D.
University of Virginia Health System,
Charlottesville, VA
Enhancing immune therapy for brain metastases with focused ultrasound
In partnership with the Focused Ultrasound Foundation

Gavin Peter Dunn, M.D., Ph.D.*
Washington University School of Medicine,
St. Louis, MO
Leveraging focused ultrasound to enhance immunogenicity and liquid biopsy in glioblastoma
In partnership with the Focused Ultrasound Foundation

Amy K. Kim, M.D.
Johns Hopkins University School of Medicine, Baltimore, MD
Investigating immune checkpoint biomarkers in tissue and peripheral blood of patients with fibrolamellar hepatocellular carcinoma
In partnership with the Fibrolamellar Cancer Foundation

Malcolm A.S. Moore, D.Phil.
Memorial Sloan Kettering Cancer Center,
New York, NY
The study of hematopoietic stem cells and progenitor populations in normal and cancer cells
Gar Reichman Laboratory

Cynthia L. Sears, M.D.
Johns Hopkins University School of Medicine, Baltimore, MD
Gut microbiome and the immune microenvironment of human primary and metastatic colorectal cancer
In partnership with Fight Colorectal Cancer

ANNUAL AWARDS

Rafi Ahmed, Ph.D.*
Emory University, Atlanta, GA
William B. Coley Award in Basic Immunology

Thomas F. Gajewski, M.D., Ph.D.*
University of Chicago, Chicago, IL
William B. Coley Award in Tumor Immunology

Antoni Ribas, M.D., Ph.D.*
UCLA Medical Center, Los Angeles, CA
CRI-AACR Lloyd J. Old Award in Immunotherapy

Shannon J. Turley, Ph.D.*
Genentech, S. San Francisco, CA
Frederick W. Alt Award for New Discoveries in Immunology

DONORS MAKING AN IMPACT

The hundreds of scientists we fund each year depend on the generosity of our donors, whose desire to make a difference in the lives of cancer patients is realized through their support of our organization. Together, we are creating a future immune to cancer.

In fiscal year 2018, individual, corporate, and foundation donors provided $30 million in support of our research and education programs via direct gifts, bequests and trusts, workplace giving, participation in CRI's special events, and peer-to-peer fundraising, among other ways to give.

Through the Kitchen attendees enjoy the magazine-themed party while raising funds for the CRI Irvington Postdoctoral Fellowship Program.

1. Dr. Thomas Tan conquering the first leg of his ultramarathon for CRI

2. Sagar Shah's family and friends raised over $28,000 following his death from lung cancer

3. Elise, Kiren, and Pat, the stars of *Homesick*, the cancer-comedy web series

4. John and Lauren Veronis at Through the Kitchen

5. Anne Assmus with Team CRI at the 2018 United Airlines NYC Half Marathon

To read stories of CRI donors, visit **cancerresearch.org/supporters**

DONORS

Acknowledgements listed here reflect contributions of $1,000 or more made to CRI between July 1, 2017 and June 30, 2018.

$1 million+
Bristol-Myers Squibb
Anna-Maria and Stephen Kellen Foundation
MedImmune, Inc.
The Thompson Family Foundation, Inc.

$500,000-$999,999
Estate of Charles Gray Clarke
Estate of Edward C. Dobbs and Nancy N. Dobbs
Estate of David Laurence Perrine
Revlon

$100,000-$499,999
Antonio C. Alvarez II
Anonymous (x3)
AstraZeneca Pharmaceuticals LP
Boehringer Ingelheim GmbH
Merle S. Cahn Foundation
Mr. and Mrs. Russell L. Carson
Mr. and Mrs. Maurice J. Cunniffe
Leslie and Bob Dahl
John and Jennifer Eckerson Family Foundation
Gould Family Foundation
Mr. and Mrs. Oliver R. Grace Jr.
Janet Greenfield and Peter L. Bloom
Estate of Thomas C. Henneberger
Estate of Jeannene Ann Ingram
Estate of David Isler
The Mark Foundation for Cancer Research
Merck
The Ambrose Monell Foundation
Estate of Janet V. O'Brien
Charles Z. Offin Charitable Trust
Mr. and Mrs. Andrew M. Paul
Leslie and Michael Petrick
Regeneron Pharmaceuticals, Inc.
Gary D. Reinboth and Lois K. Reinboth Charitable Remainder Annuity Trust
Mr. and Mrs. Brian Riano
Robertson Foundation
The Rosenblatt Charitable Trust
Betsy and Paul Shiverick / Shelter Hill Foundation
Targovax
Purva and Andrew Tsai
The Wildflower Foundation
Estate of Agathe Wulkan

$50,000-$99,999
AbbVie Inc.
Anonymous (x2)
The Kamini and Vindi Banga Family Trust
The Jeanne E. and Jacob A. Barkey Memorial Fund
Justin James Bartson Trust
Mr. and Mrs. Edgar R. Berner
Jennifer L. Brorsen and Richard M. DeMartini
Estate of Margaret Christine Clark
Ann and Geoffrey O. Coley
Frederic R. Coudert Foundation
Rose Marie Craig Trust
Debevoise & Plimpton LLP
Exelixis
Mr. and Mrs. Sean P. Fahey
Fibrolamellar Cancer Foundation
Mr. and Mrs. Victor Ganzi
Genentech
GSK
Hagedorn Fund
Juno Therapeutics
Marion Esser Kaufmann Foundation
F.M. Kirby Foundation, Inc.
Judy and Leonard Lauder
Lisa Lee and Peter Zhou
Estate of Dale G. and Marilyn J. Marshall
Andy and Tom Mendell
Estate of Stella Milburn
Orinoco Foundation
Linda C. Pinkus Fund
The Bruce Ratner Family Fund
Edmond J. Safra Foundation
Sanofi Genzyme
The Frank V. Sica & Colleen McMahon Foundation
Sharzad and Michael Targoff
Ueberroth Family Foundation
Estate of June Ada Ventura
Mr. and Mrs. Searle Wadley
The Wasily Family Foundation, Inc.
Jim Weiss, W2O Group

$25,000-$49,999
Amgen Inc.
Yacov Arnopolin

DONORS (CONT.)

Edith C. Blum Foundation, Inc.
Estate of Mary A. Capaldi
Leo W. and Lilyan E. Cole Fund
The John and Christine Fitzgibbons Foundation
Sophie Garafola
Georgia and Don Gogel
Goldman Sachs & Co.
Herman B. Golub Charitable Trust
Green Charitable Foundation, Inc.
Joyce Green Family Foundation
Mary Gurster
Estate of Inez Stuart Hiller
The Immunotherapy Foundation
Mr. and Mrs. Kenneth G. Langone
Mr. and Mrs. Ronald Lauder
Mr. and Mrs. Alexander P. Lynch
Anthony Ma
Elizabeth and Thomas Maentz
Estate of Marilyn Lou Miller
Morgan Stanley & Co.
Mr. and Mrs. Jacques C. Nordeman
Anna Oschwald Trust
Estate of Albert A. Ottinger
Plex, Inc.
David M. Polen Retirement Plan Trust
The Edward John and
Patricia Rosenwald Foundation
Jane and James Stern
Walter & Louise Sutcliffe Foundation
Lauren and John Veronis
Tali and Boaz Weinstein
Whiting Foundation
David Zwirner Gallery LLC

$10,000-$24,999
ACEA Biosciences, Inc.
Adaptimmune LLC
Anonymous (x6)
Rose M. Badgeley Residuary Charitable Trust
H.G. Barsumian MD Memorial Fund
Elizabeth and Charles Beck
Curtis Bergan
Susan and Jim Blair
Bloomberg Philanthropies
Bonbright Family Foundation
Bondi Foundation
Brindley Charitable Fund
Richard E. Capri Foundation
Hester Chan
Cisco
Citigroup Global Markets, Inc.
Karen and Matthew Crews
Cupid Foundations, Inc.
Mr. and Mrs. Glenn J. DeSimone
The Eagle Rock Charitable Foundation
Albert Nathan Eisenberg Charitable
Foundation Trust
Eli Lilly & Company
Thomas G. English
Alixandra Englund
Samuel Freeman Charitable Trust
Estate of Rhoda Gilson
Clyde W. Goldbach
Goulder Family Foundation
Jennifer Grant
Gratis Foundation
Gregg Electric, Inc.
Estate of Noreen Bryce Gruebl
Shirley & Burt Harris Family Foundation
Marlene Hess and James D. Zirin
Estate of Gerald John Humpfer
The Hurlbert Family Foundation
Immudex
Inlanta Mortgage, Inc.
Mr. and Mrs. Silas G. Johnson
James Jung
Kantor Gallery
The Karev Foundation, Inc.
The Kauffmann Foundation, Inc.
Kirkland & Ellis Foundation
Robert D. Klett
Rachel Rutherford Englund Knapp
Johann Konig
Estate of Rose L. and Morris Kraft
Mr. and Mrs. Dilip Kumar
L J M Partners, Ltd.
The Florence & Edgar Leslie Charitable Trust
The Longhill Charitable Foundation
Larry L. Luing Family Foundation
Jill N. Lynch Trust
Estate of Aries Manning Jr.
The Marc Haas Foundation
Nancy L. Mauro
Mr. and Mrs. Wesley McDonald
Estate of Sharon H. McGowan
Emil and Toby Meshberg
Estrella B. Molina Revocable Trust
Mr. and Mrs. Richard P. Morgenstern
Lee Moy Family Foundation
MUFG

DONORS (CONT.)

Novartis Pharmaceuticals Corporation
PDT, Inc.
Harlan Peltz
Ms. Perri Peltz and Mr. Eric Ruttenberg
Sandra B. Phelps Family Trust
Posillico-Tully Joint Venture
Andrea and Andrew Potash
Premium Guard Inc.
Karen E. and Jay Ptashek
Quadra Productions, Inc.
Estate of Barbara Reid
Gabriela and Carlos Rodriguez-Pastor
Eloy Roybal Revocable Trust
Adolph & Ruth Schnurmacher Foundation, Inc.
June and Paul C. Schorr III
Loncar Investments LLC
The Edith M. Schweckendieck Trusts
Padmanee Sharma, M.D., Ph.D.,
and James P. Allison, Ph.D.
Jeanne and Herb Siegel
Kenneth Squire
Joseph H. Stahlberg Foundation
Stainman Family Foundation
Donald Tractenberg
Anne Travalia
Estate of Zelda M. Uthe
Mr. and Mrs. Ronald G. Weiner
Clare Welch and Joseph Welch
Wells Fargo Bank, N.A.
The Wiggins Foundation, Inc.
Raymond H. Williams
Jay Richard Yerkes

$5,000-$9,999
Annette and Jeff Adams
Dominic J. Addesso
Advaxis, Inc.
Frank Alberico
Patrick Allare
Robert G. Andrews
Anonymous (x11)
John Arnhold
Donna and Walter P. Baldwin
The Robert J. Bauer Family Foundation
Lawrence B. Benenson
Steve and Kelly Bloom Charitable Fund
Elizabeth Brown
The Henry W. Bull Foundation
Jeffrey A. Burki
Della Calce Private Foundation, Inc.
Jeannine M. Camarda and Paul Camarda
Celgene Corporation
James M. Citrin
Austin D. Cohen
Continental Grain Foundation
Jeffrey D. Denard
Estate of Elmer J. Dreher
Thea Duell and Peter Cook
EisnerAmper LLP
Juan M. Elizondo
Energy Capital Partners Management LP
Frank M. Ewing Foundation, Inc.
John E. Ferguson
Fir Tree Special Opportunities Fund III, LP
Margot E. Freedman
Charles Freeman
G2 Foundation
The Joan C. & David L. Henle Foundation
Daniel Hulseberg
In-Cyber Vision, LLC
Inovio Pharmaceuticals, Inc.
The Arthur L. Jacobson Charitable Fund at
The Community Foundation
Estate of Betty Wood Jacques
Kate and Jeff Jaenicke
The Johnson Family Foundation, Inc.
The Helen L. Kay Charitable Trust
Kramer Levin Naftalis & Frankel LLP
Dr. Donald Kuspit
Larry Leeds
Jacquelyn M. Lester
Jenny Lin
Lufkin Legacy Foundation
Marsha Lysen and Dennis Peddecord
Laurie and Jay Mandelbaum
Tungare Manohar Family Foundation
Mr. and Mrs. Christopher L. Marhofer
Evan McDonald-Stewart
Bruce Meyers
Karen Mitchell
Mr. and Mrs. Michael D. Moy
Bryan Gregory Munson
Dr. Jerome Myers
Nandansons Charitable Foundation
NS Cares
Justin Olson
Charles Patten
Plaza Construction LLC
William C. Porter
Lorraine Protheroe

DONORS (CONT.)

The Raether 1985 Charitable Trust
Resort Golf Club LP
Riley Contracting, Inc.
Mr. and Mrs. Herald L. Ritch
Rockin' Against Cancer
Dorothy S. Rose
The Edward John and Patricia Rosenwald Foundation
Susan A. Rouse
Janet M. Satz
Mr. and Mrs. David T. Schiff
Seaman Family Foundation
Michael Charles Sharp
SkiHi Enterprises Charitable Foundation
Geraldine and Ernest Smith
Michael Sorensen
Dr. David Staunton
Allison and Leonard N. Stern
Stuntz Family Foundation
The Sunshine Foundation
Susan Swank
The Thom Family Foundation, Inc.
Mr. and Mrs. Andrew H. Tisch
Troutman Sanders LLP
Turner Construction Company
Ullmann Family Foundation
Mr. and Mrs. Adam White
Rick Wilbur

$1,000-$4,999
Adobe
Mr. and Mrs. Anthony Aellen
Enrique L. Albert
Darrell Allen
Jane B. Allen
Audrie and Todd Alsdorf
Dr. Amy Alspach
Roberta M. Amon
Kurt Amoth
David Anderson
Mr. and Mrs. Ed Anderson
Gretchen M. Anderson
Jean and Dale Anderson
Justin H. Anderson
Sandra J. Anderson
Scott R. Anderson
The Andre Family Charitable Fund
Chris Andrews
Anonymous (x65)
Samuel Antill
Applied Materials Foundation
Arent Fox LLP
Timothy Arndt
Jan Aronson
Jeanne L. Asplundh
Rumana Azad
Azeredo Cosmetics LLC.
Katherine and Mark Babin
Backman Research Foundation
Baird Foundation Inc.
Gail and Robert Balsley
Joseph Bank
Bank of America
Charles B. Banks
Mr. Curtis K. Barker
Pamela S. Barry, Ph.D. and Thomas W. Schneider, Ph.D
Gerald Bartolomucci
Mr. and Mrs. Jeffrey Barton
William B. Batte
James W. Beach
Mr. and Mrs. Gerald Becker
Margie Becker-Lewin
Mr. and Mrs. Everett A. Bell
Mr. and Mrs. Jonathon Berezinski
Mary K. Berggren
Susan Bergtraum Charitable Giving
Irene M. and Edward M. Bermas
Adler Bernard
Murat Beyazit
Mr. and Mrs. Larry D. Billen
Amanada and Sean Billow
The Birchwood Country Club Incorporated
Cathie Black and Tom Harvey
Dr. Frank S. Black Jr.
Mr. and Mrs. James Black
Jeffrey A. Blackard
BlackRock
Jeff Blackwell
Mr. and Mrs. John Blanchard
Barry Blecher
Mr. and Mrs. Charles D. Blitstein
Mr. and Mrs. Gregg Bloom
Melinda and Richard Boice
John E. Bonds
Steve Booren
Genevieve and Steve Borbas
Bower Family Donor Fund
Lisa and David Boyle
BP Foundation, Inc.

Mr. and Mrs. Oren Bramson
Maria Branco
Marsha S. Brand
John E. Branzell
Paola Bravo
Ms. Marie Brenner and Mr. Ernest Pomerantz
Dr. and Mrs. Andrew Bries
Christian W. Brinkman
Paul Briski
Mr. and Mrs. Daniel Brodsky
Mr. and Mrs. David M. Brown
Dr. Joyce Brown and Mr. Carl McCall
Sam Brown
James C. Buehrle
Judith Burden
Mr. and Mrs. Joseph H. Butterfield
C.R. Bard
CA Technologies
Pat and Gil Caffray
Denise and John Calicchio
Mr. and Mrs. Frank C. Cameron
Kimberly Campbell and Edgar Sabounghi
Robert Campbell
Robert L. Campbell
Lynn and Liborio Campo
Katherine Campodonico
The Cardoso Family Fund at the East Bay Community Foundation
Virginia and Edward Caress Family Fund
Mr. and Mrs. Matthew J. Carhart
Susan Carlson
Sylvia and Bob Carnes
Christopher Carroll
Dr. and Mrs. Bradford E. Carson
Ann Carter
Mr. and Mrs. Robert A. Carter
Grant Casstevens
Catalina Barber Corporation
Dr. Jacob M. Chacko
Steven M. Chagnon
Kaeshi Chai
Pamela Chan and Allan Harvey
David R. Chapman
Dr. Hamilton Y. Chong
Dr. and Mrs. John Christensen
Mr. and Mrs. Daniel K. Clark
Olivia and Mark Clark
Lisa Clawson
Simon Clephan
John Cogman
Eric Cohen
Jackie I. Cohen
Steven Cohen
Jean P. Colaco
Christopher Collins
The Colton Family Foundation
Mr. and Mrs. Robert Comer
George Conly
Taylor P. Conrad
Richard J. Contrada
Brian S. Coordsen
Corchem Corporation of Texas
Cece Cord
Mr. and Mrs. Richard Corey
Matthew P. Cotlar
Sophie G. Coumantaros
Mr. and Mrs. Ronald Couture
Claire and James Coyle
CRC Cares Foundation
William S. Credle
John, Jill, & Johnny Crowe and Daniel & Lauren Sanabria
CSX Financial Services
The Randi and Roger Cunningham Charitable Fund
Julia and John Curtis
Evelyn J. Cusack
Cypress Wealth Advisors LLC
Dakota Hills Middle School
Estate of Chesley J. Dale
Susan and Mark Dalton
Danem Foundation
Savannah Daniels
Mr. and Mrs. Bill Davies
Gregory Davies
Gary S. Dawson
Angela DeFilippis
Emily and Rutger DeQuay
John F. DeRango
John Deresky
Mr. and Mrs. Paul Dertien
Lori Devine
Mr. and Mrs. Andrew Dickman
Valerie - Charles Diker Fund Inc.
Ran Ding
Hrishi Dixit
Mr. and Mrs. Stephen Dizard
Mr. and Mrs. John H. Dobbins
Mary Anne and Dennis Dodson
Eva M. Donaldson
Darryl Dott

DONORS (CONT.)

Dr. Ronald and Beth Dozoretz
Tyra Drager
Lesley Draper and Robert Stolar
John Patrick Driscoll
Jeffrey J. Du Bois
Deborah J. Dumaine
James Dunne
Robert Durlacher
Nancy. P Durr
Ashok Dutta
Joshua Easterly
Deborah L. Echt
Melinda Edelcup
Edward Investments LP
Angela and Christian Ehemann
Mr. and Mrs. Harry C. Ehlert
Barbara Eichstedt
Electrical Contractor Magazine
Diana and Stephen Elkin
Eric Ellenbogen
Mr. and Mrs. Chris Ely
E. Joseph Evans Charitable Trust
Lacey D. Facer
Christopher Fahy
Rami N. Fakhouri
Mr. and Mrs. Benjamin Falchuk
Carmer B. Falgout
Xiaodong Fang
Steven Farago
Mary C. Farrell
Charlotte Farscht
Paul Fedchak
Minnie & Samuel Feldman Family Charitable Foundation
Lois Sessoms Fennelly
Louise Egdorf Fescine
Jorge Fis
Calvin S. Fisk
Jeanne M. Fitzsimmons, Ph.D.
John A. Flood
Thomas Foley
Mr. and Mrs. Wilbert M. Foley
Austin Fontanella
Aaron Ford
Jeff Fox
Franza-Johnson Family Fund
Freddie Mac
Freeman Family Foundation
Brandon and Michelle Freiman
Ethan Frey - Brookshire Realty
Carolyn Friel
Mr. and Mrs. Douglas Friend
The Charlene M. Fuller Family Trust
Robert Furey M.D., FACS
Patricia Gaffigan
Carolyn D. Gaites
Danny Garcia
John A. Gardner
Jarod D. Gates
Gateway School
The GE Foundation
Pastor Brian K. Gegel
Viktor Geller
Don Gentry
Mr. and Mrs. Daniel Gerding
The Chris Gethard Show
Kristen Giacobbe
Michael C. Gibbons
Gibson, Dunn & Crutcher LLP
Evelyn Gillespie
Philip H. Giroux
Mr. and Mrs. Roert Glass
Zachary and Kelly Glazer
Mr. and Mrs. David Glendinning
Mr. and Mrs. Kenneth H. Globus
Laurie and Jeffrey Goldberger
Richard Goldcamp
Denise H. Goldstein
Ellen M. Golub Charitable Foundation
Suraj Gondil
Matha Gonzalez
Meg and Bennett Goodman
Russel Gordon
Ryan Gould
Debra Granada
Walter J. Grandfield
Clair Grant
Ian M. Graziano
William Greene
George Greenleaf
Mr. and Mrs. Grimes
Kathryn Grossman
Christopher M. Grubert
Gail B. Guay
Sheldon K. Gulinson
Mrs. John Gutfreund
Jeff Gutkin
Haley and James Guzzo
Mr. and Mrs. Daniel T. Gynn
Mr. and Mrs. Talbot Hamilton

DONORS (CONT.)

Paulina Han
Hanna Family Fund
Mr. and Mrs. Robert Hanscom
J. Ira and Nicki Harris Family Foundation
Lynne A. and John A. Harris
Evan Harvey
Dr. and Mrs. William A. Haseltine
Robert Haverkamp
Willard L. Hawkins Jr.
Dr. and Mrs. James E. Heath Jr.
Donald B. Hebb Jr.
Martin Denis Hegarty
Christiaan Heijmen
Maria Cristina Anzola Heimann and John G. Heimann
Sandra Heineck
Beth and Charles Helms
Sheldon H. Herman
Stephen E. Herzog
William E. Hess
Monique M. Heyninck
Beth Hickey
Stephen E. and Jane C. Higgins Family Fund
Mr. and Mrs. Christopher Hinrichs
Jeff Holland
Mr. and Mrs. Jan Holliday
Kathleen and David Hollows
John and Mildred Holmes Family Foundaiton
Home Depot
Steven Alcantara Hoover
Marie Horton
Cheryl Houser
Tim Howard
Xue Huang
Paul J. Huchro
Jane D. Hudson
Shaun Hughbanks
HWL Family Foundation
Ross Ianev
Marian Ilitch
Corbin Imai
Intersign Corporation
E. Marion Jacknow
Frank and Marta Jager Foundation
The Janklow Family
Mr. and Mrs. Arthur H. Jerbert Jr.
Jessco LLC
JLR Holding LP
Donald Joh
Mr. and Mrs. Ken Johns
Valerie A. Johnston
Anne and John Jones
Julienne Jones
Dr. Basim Kadhim
Morton and Merle Kane Family Philanthropic Fund
Matthew Kaplan
Jessyn Katchera
Kathryn Ammerman James Legacy Foundation
Mr. and Mrs. Howard Kaye
KBKG
Kris Kehasukjaren
Nikhil Kelkar
Eileen B. and John J. Kelleher
Estate of Blanche C. Kelly
Veronica and Raymond Kelly
Denise and Richard Kerns
Arezou Keshavarz
Romel Khan
Kristine Kijowski
Mr. and Mrs. Christian A. King
Debra Knoeller
Ali and Matt Knopman
Roger M. Kohler
Ken Kokron
Mary Kooiman
James A. Kosic
Mr. and Mrs. Richard F. Kossik
Betty and Arthur Kowaloff
Kramer Foundation Inc.
Charles M. Krom
Dolores Kuhlman
Alan T. Kujawa
Susan D. Kulkarni
Mr. and Mrs. Kevin Kuntz
Perry A. Kupietz
Mr. and Mrs. Richard J. Kurtz
Mr. and Mrs. David P. Kusel
KVK Inc.
Sarah Kwon
Laine Charitable Fund
Mr. and Mrs. George Lambright
Diane Lane
Richard Larson
Marilyn and Bob Laurie Foundation
Joan Lavery
Nelson Law
Martha and Drahomir Lazar

DONORS (CONT.)

Laura Ledford
Byron S. Lee
Chris Leggetter
Morris and Lillie Leibowitz Charitable Trust
Amy and Craig Lemle
Dr. and Mrs. Philip R. Lesorgen
Mr. and Mrs. Francis L'Esperance
Mary Lynne Levy
Yang Li and Christopher Weber
Mr. and Mrs. D. Scott Lindsay
LinkedIn
Mr. and Mrs. Aaron Llanso
Helaine Lobman
Eva Lorenzotti
Mr. and Mrs. Michael R. Lorusso
George Lucas Family Foundation
Timothy and Leslie Lucas Charitable Fund
Maxwell Luce
Philip H. Lucht
Gabe Luger
Brian Luing
Chris Lujan
Donald L. Lundholm
Kathleen Lyle
Laura Mackall and Robert Manley
Susan MacLane
Barclay Macon
Melody and Chris Malachowsky
Celia and Ramesh Manne
Mr. and Mrs. Michael Maranto
Michael Fitzgerald Marek Charitable Fund
Beverly and John Marino
Robyn and Timothy Marins
Mr. and Mrs. Christopher Martin
Jane Martin and Stuart Katz
Mr. and Mrs. Redge A. Martin
Steve Martin
Allyssa Masi
Mr. and Mrs. Allen R. Mass
Dr. and Mrs. Philip S. Mastman
Andrew Matlak
Matrix Management
Chris Matthews
John D. Mauro
Jeffrey S. May
Cheryl and Roy 'Rem' Mayes
Lynn G. McAtee
Dorothy McCabe
Theresa and Glenn McCarty
Joesphina and Matthew McComiskey
William D. and Joan G. McCoy Family Foundation
Dana McDowell
Christopher McGarrigal
Peggy L. McInnis
Kate A. McKay
Robert M. McKeon
Mr. and Mrs. Thomas W. McLean
W. Patrick McMullan
Nelson Mead Fund
Medtronic Foundation
David Mehok
Judith A. Melton
WA Mercer Family Foundation
J. Douglas Merritt
Mr. and Mrs. Marc Metcalf
Ian Metrose
Christine Meuers and Steven Rau
Virginia A. Meuers
Joan K. Meyers
Christa Michalaros
Donald and Diane Miller
Diane Mohr
Afshin Momtaz
Karen M. Monson
Anne B. Moore and Allen Moore III
Francine Moore
Mr. and Mrs. Paul D. Moran
Morris Softball StriKeOut Cancer
Charles Stewart Mott Foundation
Melinda Naderi
Mr. and Mrs. Uday R. Naik
Gregory M. Najda
National Mah Jongg League, Inc.
NCG Foundation
Anne and David Necker
Sergei Nedospasov, Ph.D., D.Sc.
Gregory Neichter
Genevieve Nestor and Andrew A. Brenner
Alexander Neumann
Suzanna J. Nichols
Kevin K. Nickel
Nilfisk Inc.
Mr. and Mrs. David Noshay
John Nowak
Richard Nykamp
Elizabeth & Daniel O'Connor Family Foundation, Inc.
Katherine O'Connor
Meghan Orlandi
Mr. and Mrs. John W. Orlando
Mr. and Mrs. T. J. Orlowski

DONORS (CONT.)

Alma and Fred Otto
Mr. and Mrs. William A. Otwell
Paul Painting
Dr. and Mr. Sreya Pallath
Glenn H. Palmer
Michael J. Palmer
Yvonne S. Palmer
Dr. Vernon L. Pankonin
Mr. and Mrs. Rudra Parikh
Partners Capital Investment Group, LLC
Kelly and Gerry Pasciucco
Minhaj Patel
Andrea Patineau
Michael Patnode
Stewart Paul
Franke Paulett
Paulson Charitable Foundation, Inc.
Michael Pazak
Shirley Anne Pearlman
Scott Pecullan
Mr. and Mrs. Jeffrey M. Peek
Michael Perciballi
Steven D. Perkins
Per-Lee Giving Fund
Steve B. Pert
Jeffrey A. Peterson
Scott Peterson
Mr. and Mrs. Rudy Pettinato
Elizabeth and Theodore Peyton
Mr. and Mrs. Donald Pfanz
The Pfizer Foundation
Josselin Phan
Phillips 66 Company
PIMCO
Melissa and Charles Pittman
Vickie and Rahn Pitzer
William Pohl
Eric F. Polhamus
Christopher Poole
Mr. and Mrs. Robert A. Posner
Mr. and Mrs. Dan Powers
PPE Casino Resorts Maryland, LLC
Mr. and Mrs. Robertus Prajogi
Mr. and Mrs. James Prestridge
Marvin Price
Michael Anthony Princic
Judith L. Prior
Procurement Advisors LLC
Carl Pugliese
Brad Purifoy
Qualcomm
The Quincy Moose Lodge
Ivan Radivojevic
Renate and Walter Rados
Susan Raghoobar
Mr. and Mrs. Mike Rago
Mr. and Mrs. Keith Raine
Parker Ramsdell
Randall Family Charitable Fund
Mr. and Mrs. Tom Ratchford
Sanjay Rattan
Susan and Peter Rawlinson
Terrie L. Ray
Douglas Rediker
Kristin and Michael Reed Family Foundation, Inc.
Thomas Reedy
Hulda and Michael Refermat
Estate of Michael C. Regan
Eric Reichenberg
Chad E. Richman
Mr. and Mrs. Jeffrey M. Riely
Kurt Riemenschneider
Cody Rinehart
Mr. and Mrs. David Riparbelli
Nikki Rock
Mr. and Mrs. Michael A. Roe
Brigitte and Raymond Rogerson
Diana D. Rollins
James D. Rone
Samuel Ronk
Rooster Racing International Inc.
Marc B. Rosen
Donald Rosenfeld
Roux Associates
Ricky Ruiz
Running Warehouse
Estate of Rocco E. Russo
The Rust Family Foundation
Sakata Seed Corp
Salesforce.org Foundation
Sallay Family Fund
Stanley Saltzman
Harold Sanditen
Shamba K. Sandy
Steven R. Saraniero
Patricia S. and George Sarner
Rose Ann Scamardella
Sharon and Roger Schenewerk
Frances and Howard Schloss
Family Philanthropic Fund

DONORS (CONT.)

Mr. and Mrs. William Schmale
Marvin L. Schmeiser
Gregg M. Schneider
Karen A. and Henry P. Schneider
Joanne Schoonover and Kenneth Schoonover
Dr. David N. Schrier
Barbara Schuette
Schulman Family Foundation
Henry C. Schulte and Virginia M. Schulte Foundation
Mr. and Mrs. Wayne L. Schultz
Suzanne Scrabis
Daniel H. Scrafford
Ann Sedman
Devin J. Seifer
Matthew W. Servatius
Drs. Rashu and Abhinav Seth
Constance Shapiro
Jane E. Sharp
Dr. Arlene H. Sharpe
Cynthia Sheets
George Shen
Diana Shepard
Shepard's Walk Foundation Inc.
Hambleton Shepperd
Shomos Family Foundation
Sudnya Shroff
Gregory Siebert
Bronislava Sigal
James W. Silver
Robert S. Silver
Anne Silverstein
Marc Simard
Mr. and Mrs. Jim Simonds
Konstantin Sinkevich
Scott Sklar
Eric Sloan
Lois V. Smigel
Gordon H. Smith
Julie Smith
Nora M. Smith
Ronald and Vickie Smith
Shirley C. Smith Charitable Foundation
Stephen L. Smith
Mr. and Mrs. Scott Sokol
Mr. and Mrs. Roger Soons
Alexa Spears
Michael Spyridakis
Paul J. Stagg
Mr. and Mrs. John Stamer
Edgar Stanley
Bonnie M. and Robert J. Stapleton
Ryan A. Starck
Donlad J. Stauffer
Donna Steele
Mary K. Steffens Foundation Inc.
Jamey Stegmaier
Stellar Solutions Foundation
Aaron Stern
Beatrice Stern and Jamie Niven
The Stern Investor Relations Foundations
Derek Stevens
Jeanne Stewart
Soren Stig-Nielsen
Uros Stosic
Michael L. Stowers
Mr. and Mrs. Scott A. Strobl
Rachel and Derek Strum
Bessie Svehla
Mr. and Mrs. Kok Chor Tan
Judith M. Taubman
Bernard Taylor
Daniel N. Taylor
Jean and Kenneth Telljohann
Michelle and Marcus Terry
Britt and Stephen Thal
Mr. and Mrs. Jeffery Thomas
Charles and Ramona Thompson
Pat and Bruce Thoms
James Timmerberg
Daena Title
Jacqueline S. Tornes
Alain Tranchemontagne
Michael Tronske
Mr. and Mrs. John Trousdale
Katharine N. Trumble
Mr. and Mrs. Paul Trunk
Chung-Ta Tsai
Robyn and Mark Tsesarsky
Mr. and Mrs. John Tucker
Shaun Tull
Ahmet K. Tureyen
U.S. Family Foundation, Inc.
James Utaski
Utility Contracting Co.
Joseph S. Valdez
Janet and Jeffrey Valentine
Anne and Philip Vander Haar
Mr. and Mrs. Bill Vanderhoef
Belkis Vasquez-McCall

DONORS (CONT.)

Verstappen Family Foundation
Village of Long Creek Maintenance Corporation
VincentBenjamin Group LLC
Millie Viqueira and Steve Miller Fund
Steven Vlaminck
John Vogel
Mr. and Mrs. Lance Volland
Julie D. Volosin
Greta Von Hagge
Tonya Wade
Joseph Waldman
The Kathleen B. and Charles R. Walgreen III Foundation
Robert Walker
Mark W. Waller
Richard N. Walsh
Carrie L. Walworth
Debbie J. Ward
Mr. and Mrs. Benton Warder
Paul M. Warner
Linda Warren
Mr. and Mrs. David Watkins
David C.L Watson
Doris and Glen Weaver
The Weingarten Schnitzer Foundation
Thomas Welling
Wells Fargo
Elizabeth G. Weymouth
Gerald I. White
Caren P. Williams
Richard J. Wilson
Carole and Michael Witte
AC Wittmer Charitable Fund
Gary Woehlke
Wolzinger Family Foundation
Joanne L. Woodruff
Mr. and Mrs. William Worthington
WowToyz
The David D. and Mary Ellen Wright Family Fund
Tsae Wu
Mr. and Mrs. Brian Yaeger
Stephen Yegelwel
Jeanine Yost and Alexander Bankovich
Lauren and Paul Young
Jennifer and Eddy Zervigon
Yan Zhao
Mr. and Mrs. Balkir Zihnali
Julie Zimmerman
Barbara and Marc Zuckerman
Joan R. Zuckerman
Tawnya Zwicker
Anita L. and Richard B. Wyman

1. Family and coworkers host the second annual Donny G. Memorial Golf Tournament.

2. Alissa Ren raised a total of $8,150 for her first half marathon in Singapore in May 2018.

FINANCIAL HIGHLIGHTS

88 PERCENT OF EXPENSES DEDICATED TO PROGRAMS

$384 MILLION INVESTED SINCE 1953

PUTTING DONOR DOLLARS TO WORK

ALFRED R. MASSIDAS
Chief Financial Officer

Donor trust is our most valued asset. To earn and keep this trust, we hold ourselves to the highest standards of accountability and transparency when communicating the financial health of the Cancer Research Institute. Our financial records are kept according to best nonprofit accounting practices.

With expert guidance from our Board of Trustees Finance and Audit Committee, we work to ensure that CRI's financial assets not only perform at the highest levels, but also that these funds entrusted to us by the public are managed prudently. Our consistent and proven adherence to fiscal integrity has earned CRI the highest accolades from charity watchdog organizations such as the Better Business Bureau Wise Giving Alliance, Charity Navigator, and GuideStar, among others.

As part of our commitment to building and maintaining a foundation of trust with our donors and the public, we open our books annually for inspection and verification by independent auditors. EisnerAmper has conducted an independent audit of the Cancer Research Institute's financial activities for fiscal year 2018 (July 1, 2017 to June 30, 2018). We provide highlights here, which reflect revenues of $33 million, expenses of $31.5 million, and end of year net assets of $52.1 million.

To access our complete audited financial statements, IRS forms 990, and annual reports, visit **cancerresearch.org/financials**

TOTAL SUPPORT AND REVENUES
$33.0 MILLION



Contributions
$24 million, 73%

Investments and Other
$3 million, 9%

Bequests and Memorials
$4.2 million, 13%

Special Events
$1.8 million, 5%

TOTAL EXPENSES
$31.5 MILLION



Research
$21.7 million, 69%
$25.1 million awarded minus $3.4 million in early terminations from grants made in prior years

Science, Medical, and Research Information and Communications
$4.8 million, 15%

Marketing and Development
$2.2 million, 7%

Administration
$1.5 million, 5%

Allowance for Uncollectible Accounts
$1.4 million, 4%

END OF YEAR NET ASSETS
$52.1 MILLION

GOVERNANCE & GUIDANCE

HARNESSING EXPERT OVERSIGHT

Volunteer scientific and business leaders provide essential help to the Cancer Research Institute, not only through academic and financial support, but also through astute governance and active participation in the organization's initiatives.

BOARD OF TRUSTEES

CHAIRMEN

Paul C. Shiverick
Co-Founder
Seminole Management Company, Inc.
New York, NY

Andrew K. Tsai
Managing Principal
Chalkstream Capital Group, L.P.
New York, NY

VICE CHAIRMEN

Edgar R. Berner
Partner
John Lang, Inc.
New York, NY

John B. Fitzgibbons
Chairman and CEO
Basin Holdings US LLC
New York, NY

Donald J. Gogel
Chairman and CEO
Clayton, Dubilier & Rice, LLC
New York, NY

Jacques C. Nordeman
Chairman
Nordeman Grimm, Inc.
New York, NY

Andrew M. Paul
Managing General Partner
Enhanced Equity Funds
New York, NY

TREASURER

Geoffrey O. Coley
International Business Head
Mitsubishi UFJ Securities (USA), Inc.
New York, NY

SECRETARY

Thomas G. Mendell
Private Investor
T.G. Mendell Corp.
New York, NY

MEMBERS

Antonio C. Alvarez II
Co-Founder and Chief Executive Officer
Alvarez & Marsal Holdings, LLC
New York, NY

Yacov Arnopolin
Portfolio Manager,
Emerging Markets
PIMCO
New York, NY

Kamini Banga
Chair
The Kamini and Vindi Banga Family Trust
Handelsbanken Wealth Management
London, United Kingdom

Peter L. Bloom
Brooklyn, NY

Jennifer L. Brorsen
Bronxville, NY

James M. Citrin
Leader, CEO Practice
Spencer Stuart
Stamford, CT

W. Robert Dahl
Principal
WRD Capital
Darien, CT

Glenn J. DeSimone
Vero Beach, FL

John E. Eckerson
Pound Ridge, NY

Sean P. Fahey
Founding Member and
Co-Chief Investment Officer
Claren Road Asset Management
New York, NY

Margot E. Freedman
Larchmont, NY

Oliver R. Grace Jr.
President
Associated Asset Management, Inc.
Palm Beach, FL

Sandra Coudert Graham
Oyster Bay, NY

Michael M. Kellen
Director of First Eagle Holdings, Inc.
Vice Chairman of First Eagle
Investment Management, LLC
New York, NY

Alexander P. Lynch
Partner
White Deer Energy
New York, NY

Michael J. Petrick
Greenwich, CT

Brian Riano
Co-Founder and CEO
Claren Road Asset Management
New York, NY

Lief D. Rosenblatt
Partner
ENE Investco Management
New York, NY

Frank V. Sica
President
Tailwind Capital
New York, NY

James A. Stern
Chairman and Founder
The Cypress Group, LLC
New York, NY

Robert Stolar
Managing Director
Morgan Stanley
New York, NY

Michael B. Targoff
Vice Chairman of the Board of
Directors
Loral Space & Communications
New York, NY

Diane Tuft
New York, NY

Heidi J. Ueberroth
Director
Pebble Beach Company
Pebble Beach, CA

Lauren S. Veronis
New York, NY

Ronald G. Weiner
President
Perelson Weiner LLP
New York, NY

Jim Weiss
Founder and CEO
W2O Group
San Francisco, CA

Peter Zhou
Senior Managing Director
Coatue Management
New York, NY

TRUSTEES EMERITI

Carter F. Bales
Chairman and Managing Director
NewWorld Capital Group, LLC
New York, NY

Howard P. Berkowitz
HPB Associates
New York, NY

Donald G. Calder
Chairman
Clear Harbor Asset Management
New York, NY

Stuart P. Davidson
Managing Director
Labrador Ventures
San Francisco, CA

Bruce D. Dixon
Retired Partner
Ernst & Young
Greenwich, CT

Mrs. Charles G. Gambrell
Charlotte, NC

William O. Grabe
Advisory Director
General Atlantic LLC
Greenwich, CT

Joyce Green
Westhampton Beach, NY

Ann W. Jackson
New York, NY

Arthur L. Jacobson
Vice President, Investments
Smith Barney
Indian Wells, CA

Robert A. Posner
Managing Director
Commonwealth Holding, LP
Brookline, MA

Julian H. Robertson Jr.
Chairman
Tiger Management, LLC
New York, NY

ASSOCIATE BOARD

CRI ASSOCIATE BOARD ROSTER

CHAIRMAN

Trent Kososki
Partner
Energy Capital Partners
Houston, TX

MEMBERS

Adler Bernard
Vice President and Assistant General Counsel
JPMorgan Chase & Co.
New York, NY

Ross Bruck
Vice President
TPG Sixth Street Partners
New York, NY

Rada Cevher
Director
Gartner
Stamford, CT

Robert W. Chen
Senior Vice President
Morgan Stanley
New York, NY

Eash Cumarasamy
Executive Vice President, Finance
Basin Holdings
New York, NY

Isabelle Franks
Lead, Corporate Communications
MUFG
New York, NY

Andrew Goldman
Managing Director
Anchorage Capital Group
New York, NY

Matt Goldman
Portfolio Manager and Executive Director
UBS O'Connor
New York, NY

Jack Griffin
Analyst
MUFG
New York, NY

Tyler Hassen
President
Basin Drilling Tools
CEO
Wenzel Downhole Tools
Denver, CO

Samantha Knapik
Senior Manager, Partnerships & Business Development
Global Commercial Financial
American Express
New York, NY

Jennifer Kososki
Real Estate Investment Manager
Houston, TX

Pär Lindstrom
Managing Partner
i(x) Investments
New York, NY

Taylor Paul
Associate
Sopris Capital
New York, NY

Tomas Peshkatari
Director, Global Energy and Power Infrastructure
Blackrock
New York, NY

Philip Shapiro
Associate Attorney
Gibson, Dunn and Crutcher, LLP
New York, NY

Courtney Shields
Principal Designer
Courtney Shields Designers
Denver, CO

Josh Tinch
Senior Customer Success Manager
TicketManager
New York, NY

SCIENTIFIC ADVISORY COUNCIL

DIRECTOR

James P. Allison, Ph.D.
The University of Texas
MD Anderson Cancer Center
Houston, TX

ASSOCIATE DIRECTORS

Glenn Dranoff, M.D.
Novartis Institutes for BioMedical Research
Cambridge, MA

Carl F. Nathan, M.D.
Weill Cornell Medicine
New York, NY

Ellen Puré, Ph.D.
University of Pennsylvania
Philadelphia, PA

Robert D. Schreiber, Ph.D.
Washington University School of Medicine
St. Louis, MO

Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center and
Ludwig Cancer Research
New York, NY

MEMBERS

Frederick W. Alt, Ph.D.
Howard Hughes Medical Institute,
Boston Children's Hospital and Harvard Medical School
Boston, MA

Richard Axel, M.D.
Columbia University Medical Center
New York, NY

Nina Bhardwaj, M.D., Ph.D.
Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
New York, NY

Harvey Cantor, M.D.
Dana-Farber Cancer Institute
Boston, MA

Jonathan S. Cebon, Ph.D., FRACP
Olivia Newton-John Cancer Research Institute and Austin Health
Melbourne, Australia

Vincenzo Cerundolo, M.D., Ph.D.
MRC Human Immunology Unit,
University of Oxford
Oxford, United Kingdom

Max D. Cooper, M.D.
Emory University School of Medicine
Atlanta, GA

Lisa M. Coussens, Ph.D.
Oregon Health & Science University
Portland, OR

Peter Cresswell, Ph.D.
Yale School of Medicine
New Haven, CT

Charles G. Drake, M.D., Ph.D.
Herbert Irving Comprehensive Cancer Center,
NewYork-Presbyterian/Columbia University Medical Center
New York, NY

Michael L. Dustin, Ph.D.
Kennedy Institute of Rheumatology
University of Oxford
Oxford, United Kingdom

Richard A. Flavell, Ph.D., FRS
Yale School of Medicine
New Haven, CT

Thomas F. Gajewski, M.D., Ph.D.
The University of Chicago Medicine
Chicago, IL

Laurie H. Glimcher, M.D.
Dana-Farber Cancer Institute
Boston, MA

Philip D. Greenberg, M.D.
University of Washington School of Medicine and Fred Hutchinson Cancer Research Center
Seattle, WA

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA

Patrick Hwu, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Elizabeth M. Jaffee, M.D.
Bloomberg-Kimmel Institute for Cancer Immunotherapy,
Johns Hopkins Medicine
Baltimore, MD

Carl H. June, M.D.
Abramson Cancer Center,
Perelman School of Medicine,
University of Pennsylvania
Philadelphia, PA

Michael Kalos, Ph.D.
Janssen Pharmaceuticals
Spring House, PA

Michael Karin, Ph.D.
University of California, San Diego
La Jolla, CA

John M. Kirkwood, M.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Alexander Knuth, M.D.
National Center for Cancer Care and Research, Hamad Medical Corporation
Doha, Qatar

Lewis L. Lanier, Ph.D.
University of California, San Francisco
San Francisco, CA

Hyam I. Levitsky, M.D.
Replimune
Woburn, MA

Dan R. Littman, M.D., Ph.D.
Skirball Institute of Biomolecular Medicine,
NYU Langone Medical Center
New York, NY

Nils Lonberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA

Tak W. Mak, Ph.D., D.Sc., FRSC
The Campbell Family Institute for Breast Cancer Research,
University Health Network,
University of Toronto
Toronto, Canada

SENIOR STAFF

Alfred R. Massidas
Chief Financial Officer and Director of Human Resources

Sharon Slade
Director of Strategic Initiatives

STAFF

Arthur N. Brodsky, Ph.D.
Science Writer

Angela Bui
Strategic Initiatives Coordinator

Ryan Godfrey
Grants Administrator

Cierra Howard
Community Fundraising Coordinator

Rupinder Kaur
Senior Manager of Operations and Officer of Planned Giving

Marla S. Lawson
Associate Director of Corporate and Foundation Relations

Jasmine Lingard
Senior Manager of Special Events

Melinda Lopez
Receptionist and Community Fundraising Coordinator

Deanne Marbach
Development Officer

Katherine McCluskey
Project Coordinator

Shasell Negron
General Manager / Workplace Giving Campaign Manager

Alice Northover
Senior Marketing Manager

Caroline Offit
Associate Director of Patient Engagement

Hannah Ressinger
Assistant to the CEO and Development Assistant

Kajol Sankar
Donation Processing Assistant

Chary Sathea
Social Media Manager

Alexa Schles
Graphic Designer

Devi Sharma
Donations Processing Manager

Jun Tang, Ph.D.
Senior Manager, CRI Venture Fund and Clinical Accelerator

Jia Xin "Annie" Yu, Ph.D.
Research Analyst

Qing Hua Zhang
Controller

CONSULTANT

Laura Pearce, M.S., B.Sc.H.
Head of Clinical Alliances and Program Management

GIVING TO CRI

The Cancer Research Institute has a long tradition of responsible stewardship of donor funds. We receive the highest marks from charity watchdog groups, including four out of four stars from Charity Navigator, the platinum seal of transparency from GuideStar, and an "A" grade from CharityWatch. CRI also meets all 20 standards of the Better Business Bureau Wise Giving Alliance. Donors to CRI can be confident that their donation, in any amount, will do the most good possible.

CASH

Donations by check or credit card may be sent directly to the Cancer Research Institute or processed through our secure website at **cancerresearch.org/donate**.

PROPERTY OTHER THAN CASH

Donating securities, automobiles, and similar properties can often be a tax-efficient method for making a meaningful gift to CRI. Visit **cancerresearch.org/ways-to-give**.

WORKPLACE GIVING PROGRAMS

Ask your human resources department if your company has a plan through which you can contribute to CRI, or contact us to learn how to set up a program at your workplace. Visit **cancerresearch.org/workplace-giving**.

EMPLOYER MATCHING GIFTS

Contact your human resources department to inquire if your employer matches contributions, or browse our online matching gift database to see if your company is listed at **cancerresearch.org/matching-gifts**.

PLANNED GIFTS

Make a bequest to CRI through a living trust or in your will as a beneficiary of cash, securities, or personal property. Your bequest should include CRI's federal tax ID number (13-1837442) and a statement such as the following:

"I bequeath to the Cancer Research Institute, a not-for-profit corporation of the State of New York, having its principal office at 29 Broadway, Floor 4, New York, New York 10006-3111, the sum of $_____ for its general operating purposes."

You should, of course, always consult your attorney and tax advisor for the formal writing of your will and to discuss the tax implications of any form of planned giving. Learn more online at **legacy.cancerresearch.org**.

COMMUNITY FUNDRAISING

Want to hold a bake sale to raise money for cancer research? How about a fashion show, dinner, or a concert? Maybe you're getting married and would prefer guests give to charity in lieu of gifts. We offer support for these and other fundraising ideas. To learn more about how you can organize your own special event and become a part of Team CRI, visit **cancerresearch.org/fundraise**.

FOR CORPORATE PARTNERS

No one organization, company, or group can solve the cancer problem alone. It takes collaboration to change the course of cancer. CRI actively seeks out and welcomes opportunities to work with others to develop educational and awareness-building programs designed to advance the pace of progress in cancer immunotherapy research. Contact Sharon Slade at sslade@cancerresearch.org or (212) 688-7515 x230 to learn more.

In 2015, Ron was diagnosed with stage 4 colorectal cancer. He received traditional, but debilitating, chemotherapy treatment for nine months. He could neither eat nor sleep, and his devastated wife, Maria, searched for other options. In 2016, after learning he carried a genetic mutation linked to Lynch syndrome, a genetic condition that increases risk of colorectal and certain other cancers, Ron began receiving a combination of two immunotherapies on a clinical trial at University of Pittsburgh Medical Center. Today, Ron continues to receive the combination as part of routine care and, for the past two years, has had no evidence of disease progression.

Watch Ron's immunotherapy story at **cancerresearch.org/ron**

To help you make the most fitting and fulfilling contribution to CRI, please contact our Office of Institutional Advancement at (212) 688-7515 or send an email to advancement@cancerresearch.org.

NATIONAL HEADQUARTERS

29 Broadway, Floor 4
New York, NY 10006-3111
Tel. (212) 688-7515
Toll-Free (800) 99-CANCER
Fax (212) 832-9376
Email info@cancerresearch.org

CANCERRESEARCH.ORG

65 YEARS IN IMMUNOTHERAPY

CANCER RESEARCH INSTITUTE